Peripheral Nerve Society

Officers of the Society
Eva L. Feldman, President
Douglas W. Zochodne, President-Elect
David R. Cornblath, Secretary/Treasurer
Amber M. Millen, Executive Secretary

Board Members
Patricia J. Armati
Richard A.C. Hughes
Giuseppe Lauria
Mary M. Reilly
Angelo E. Schenone
Michael E. Shy
A. Gordon Smith
Hugh J. Willison

Scientific Program Committee
Michael E. Shy, Chair
M. Laura Feltri, Co-Chair
Wendy M. Campana
Angelika F. Hahn
Ahmet Höke
Jean-Marc Léger
Mary M. Reilly
James W. Russell
Zarife Sahenk
J. Robinson Singleton
Hugh J. Willison

Conference Organizing Committee
Local Organizing and Liaison Committees
(Universitätsklinikum Würzburg)
Klaus V. Toyka, Würzburg, Chair
Claudia L. Sommer, Würzburg, Co-Chair
Guido Stoll, Würzburg
Hans-Peter Hartung, Düsseldorf
Rudolf Martini, Würzburg
Michael Sendtner, Würzburg

CME Joint Sponsorship
University of California, San Diego School of Medicine
The Peripheral Nerve Study Group (PNSG) had its origins in a meeting organized by A. K. Asbury in Carville, Louisiana, in 1974. The success of the meeting led to the formation of the Peripheral Nerve Club, later changing its name to the PNSG, to bring together clinicians and basic scientists interested in peripheral neuropathy and the neurobiology of peripheral nerve. Meetings were held every two years, successively. The Executive Committee consisted of all those who had organized meetings. The PNSG became affiliated to the Research Group on Neuromuscular Diseases (RGND) of the World Federation of Neurology and the members of the Executive Committee of the PNSG were ex-officio members of the Executive Committee of the RGND, responsible for organizing the quadrennial International Congress on Neuromuscular Diseases.

The Peripheral Neuropathy Association of America was formed in 1983 with the intention of sponsoring meetings devoted to areas of development in the field of peripheral nerve disease.

In 1990 the Board of the Association voted to change the name to the Peripheral Neuropathy Association (PNA).

In 1994 the Peripheral Neuropathy Association and the Peripheral Nerve Study Group amalgamated into the Peripheral Nerve Society (PNS). The Society sponsors scientific meetings on a periodic basis. The Society has a membership and the activities are directed by a Board.
Past Meetings of the PNAA and PNA
  1984  Keystone, Colorado
  1985  Keystone, Colorado
  1986  Hilton Head Island, South Carolina
  1988  Halifax, Nova Scotia, Canada
  1989  Maui, Hawaii
  1990  Oxford, England
  1992  Rapallo, Italy

Past Meetings of the PNSG
  1974  Carville, Louisiana
  1975  Rochester, Minnesota
  1977  Airlie House, Virginia
  1979  Wye College, Kent, England
  1981  Shakertown, Kentucky
  1983  Fontevraud, France
  1985  Mürren, Switzerland
  1987  Lake Couchiching, Ontario, Canada
  1989  Padua, Italy
  1991  Arden House, New York
  1993  Boppard, Germany

Past Meetings of the PNS
  1994  Saint Paul, Minnesota
  1995  Antalya, Turkey
  1997  Cambridge, England
  1999  La Jolla, California
  2001  Tyrol, Austria
  2003  Banff, Canada
  2005  Tuscany, Italy
  2007  Snowbird, Utah
Major support for the meeting was provided by:

Baxter BioScience (USA)
Baxter Healthcare SA (Switzerland)
CSL Bioplasma (Australia)
Eli Lilly and Company (USA)
GBS/CIDP Foundation International (USA)
Kedrion S.p.A. (Italy)
National Institutes of Health (USA)
Octapharma AG (Switzerland)
Talecris Biotherapeutics (USA)
Verein der Freunde und Förderer der Neurologischen Klinik (Germany)

Generous contributions were also received from:

Allergan, Inc. (USA)
Athena Diagnostics, Inc. (USA)
Baxter Healthcare Ltd (UK)
Boehringer Ingelheim Pharma GmbH & Co KG (Germany)
Charcot-Marie-Tooth Association (USA)
Eisai Co., Ltd (Japan)
Fold Rx Pharmaceuticals, Inc. (USA)
Genzyme Corporation (Germany)
Grünenthal-Formenti Italia (Italy)
Lilly Deutschland GmbH (Germany)
Mitsubishi Pharma Corporation (Japan)
Nihon Pharmaceutical Co., Ltd. (Japan)
Pfizer (Germany)
Sanofi-Aventis and Teva (Germany)
Takeda Pharmaceutical Co., Ltd. (Japan)

Other contributions were also received from:

Bühlmann Laboratories AG (Switzerland)
Charles River Laboratories (Italy)
GlaxoSmithKline (Germany)
LFB Biomédicaments (France)
VIASYS Healthcare Inc. (USA)
WR Medical Electronics Co. (USA)

This support is gratefully acknowledged.

The organizational assistance of Amber M. Millen was invaluable in the preparation of the meeting and program.

Cover photo: Würzburg Residenz, Würzburg, Germany
Major support for the meeting was provided by:

Baxter BioScience (USA)
Baxter Healthcare SA (Switzerland)
CSL Bioplasma (Australia)
Eli Lilly and Company (USA)
GBS/CIDP Foundation International (USA)
Kedrion S.p.A. (Italy)
National Institutes of Health (USA)
Octapharma AG (Switzerland)
Talecris Biotherapeutics (USA)
Verein der Freunde und Förderer der Neurologischen Klinik (Germany)

Generous contributions were also received from:

Allergan, Inc. (USA)
Athena Diagnostics, Inc. (USA)
Baxter Healthcare Ltd (UK)
Boehringer Ingelheim Pharma GmbH & Co KG (Germany)
Charcot-Marie-Tooth Association (USA)
Eisai Co., Ltd (Japan)
Fold Rx Pharmaceuticals, Inc. (USA)
Genzyme Corporation (Germany)
Grünenthal-Formenti Italia (Italy)
Lilly Deutschland GmbH (Germany)
Mitsubishi Pharma Corporation (Japan)
Nihon Pharmaceutical Co., Ltd. (Japan)
Pfizer (Germany)
Sanofi-Aventis and Teva (Germany)
Takeda Pharmaceutical Co., Ltd. (Japan)

Other contributions were also received from:

Bühlmann Laboratories AG (Switzerland)
Charles River Laboratories (Italy)
GlaxoSmithKline (Germany)
LFB Biomédicaments (France)
VIASYS Healthcare Inc. (USA)
WR Medical Electronics Co. (USA)

This support is gratefully acknowledged.

The organizational assistance of Amber M. Millen was invaluable in the preparation of the meeting and program.

Cover photo: Würzburg Residenz, Würzburg, Germany
The Peripheral Nerve Society (PNS) is an international organization dedicated to advancing our understanding and treatment of peripheral nervous system disease. Our members’ interests range from basic peripheral nerve biology to clinical management of peripheral nerve disease. The PNS holds an international meeting every 2 years. This meeting brings together approximately 300-400 experts and includes research presentations (both poster and platform format) as well as a series of plenary lectures by leaders in the field. There are also scheduled opportunities for open discussion of important issues. The meeting is typically held in a cloistered setting in order to facilitate informal discussion and exchange of ideas. This is the only international congress entirely devoted to the field of peripheral neuropathy. Basic scientists and clinicians come together to benefit mutually from the others’ expertise. The PNS meeting is an ideal training situation for young scientists and clinical fellows in training who want to expand their knowledge on pathophysiology and treatment of peripheral nerve diseases.

The attendees will receive updates on basic peripheral nerve pathophysiology, like axon-glia interactions, axonal transport, and regeneration. They will also be updated on diabetic neuropathies, demyelinating and inflammatory neuropathies, and hereditary neuropathies. They will learn about new treatment strategies, like axonal protection, current treatment of inflammatory neuropathies, optimal treatment of painful neuropathies. There will be break-out sessions for special interest groups to allow in-depth discussion of scientific and clinical problems.

The Peripheral Nerve Society (PNS) is an international organization of physicians and scientists dedicated to forwarding our understanding of peripheral nerve biology and disease, with the ultimate aim of developing treatments for patients with various forms of peripheral neuropathy. The PNS facilitates both basic and clinical research, physician and scientific training, and consensus development of clinical standards of care. PNS members come from a broad spectrum of academic interests including basic and clinical neuroscience, pain, anesthesiology, genetics, pathology and relevant surgical subspecialties. The interests of our members encompass all aspects of the peripheral nervous system, both clinical and scientific, and range from molecular mechanisms of disease and nerve fiber regeneration through electrophysiologic tools for diagnosis to clinical trials and research synthesis. By speaking to the leaders in the PNS and examining previous feedback from our last meeting, we were able to design the current course to meet the objectives of the PNS faculty.
**Target Audience**
The target audience for this activity includes basic scientists and clinicians in the field of peripheral neuropathy.

**Accreditation Statement**
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the University of California, San Diego School of Medicine and the Peripheral Nerve Society. The University of California, San Diego School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The University of California, San Diego School of Medicine designates this educational activity for a maximum of 22.25 *AMA PRA Category 1 Credits™*. Physicians should only claim credit commensurate with the extent of their participation in the activity.

**Cultural and Linguistic Competency**
California Assembly Bill 1195 requires continuing medical education activities with patient care components to include curriculum in the subjects of cultural and linguistic competency. It is the intent of the bill, which went into effect on July 1, 2006, to encourage physicians and surgeons, CME providers in the state of California, and the Accreditation Council for Continuing Medical Education to meet the cultural and linguistic concerns of a diverse patient population through appropriate professional development. The planners, speakers and authors of this CME activity have been encouraged to address issues relevant in their topic area. In addition, a variety of resources are available that address cultural and linguistic competency, some of which are included in your syllabus or handout materials. Additional resources and information about AB1195 can be found on our website at [http://cme.ucsd.edu](http://cme.ucsd.edu).

**Course Director**
Wendy M. Campana, Ph.D.
Associate Professor of Anesthesiology
University of California, San Diego

**Meeting Planner/Staff Coordinator**
Amber Millen
Executive Secretary, Peripheral Nerve Society
Executive Assistant, University of California, San Diego
Purpose

The major purpose of the meeting is to promote discussions between basic and clinical investigators from all fields of peripheral neuropathy research. For this reason, participants are encouraged to attend all parts of the meeting. There will be platform and poster sessions.

Recreational Program

The scientific program has been organized so that the following activities are offered:

Monday, July 6, 2009
Old City Tour
or
Walk Through Würzburger Stein Vineyard
or
Museum of Modern Art Kulturspeicher
or
Shalom Europa Jewish Congregation and Museum

Wednesday, July 8, 2009
Sommerhausen
or
Old City Tour, Museum of Modern Art Kulturspeicher, or Shalom Europa Jewish Congregation and Museum (same as Monday tours)

Coordinators

The on-site coordinator for the Society is Ms. Amber Millen.

Participants may be contacted by calling the MARITIM Hotel Würzburg at +49 (0) 931 3053-0 or faxing at +49 (0) 931 3053-900. There will be a message board for internal communications.
Friday, July 3
13:00  Meeting Registration
17:30  Buses from Congress Center to Department of Neurology
18:15  *Theodor Schwann Lecture*
       REMAK’S FIBERS, SCHWANN’S CELLS: NEW VIEWS OF AXONAL DEGENERATION AND REGENERATION
       John W. Griffin
       (Lecture Hall of the Department of Neurology)
20:00  Dinner (Restaurant: Bürgerspital)

Saturday, July 4
08:00  Meeting Registration

Scientific Session 1
“Early Glia Development”
*Chairs: Magdalena Götz and Michael Sendtner*

09:00-09:10  WELCOME ADDRESS
Michael Sendtner

09:10-09:40  NEUROGENESIS FROM GLIAL CELLS - NEW VIEWS ON REACTIVE GLIOSIS AND NEURAL REPAIR
Magdalena Götz

09:40-10:10  GLIAL CELL FUNCTIONS IN THE PERIPHERAL NERVOUS SYSTEM
Patrick Charnay

10:10-10:40  SOX PROTEINS IN DEVELOPMENT OF MYELINATING GLIA
Michael Wegner

10:40-11:00  Coffee break
“Glia-Related Growth Repulsion”
*Chairs: Mary B. Bunge and Esther Asan*

11:00-11:45  FUNCTIONAL RECOVERY AFTER CNS LESIONS BY FIBER (RE-)GROWTH AND NEW CIRCUIT FORMATION
Martin Schwab

11:45-12:30  SIGNALING AXONAL REGENERATION IN THE CNS
Marie Filbin

12:30  Lunch
Saturday, July 4 (cont.)

**Scientific Session 2**

“Neuroimmunological Aspects of Disease”

**Chairs:** Reinhard Hohlfeld and Guido Stoll

14:00-14:30 IMMUNE REACTIONS IN GENETICALLY MEDIATED DEMYELINATION

*Rudolf Martini*

14:30-15:00 IMMUNOBIOLOGY OF MUSCLE

*Reinhard Hohlfeld*

15:00-15:30 **Coffee break**

“Axonal Transport/Regeneration/Imaging”

**Chairs:** Marie Filbin and Rudolf Martini

15:30-16:00 MOLECULAR AND CELLULAR MAGNETIC RESONANCE IMAGING OF PERIPHERAL NERVE DEGENERATION AND REGENERATION

*Guido Stoll*

16:00-16:30 MOTONEURON DISORDERS

*Michael Sendtner*

16:30-17:15 **Viktor Hamburger Lecture**
COMBINATORIAL STRATEGIES TO REPAIR THE INJURED SPINAL CORD

*Mary B. Bunge*

18:15 Buses to concert

18:45-19:15 **Concert**
Old University, Aula

20:00 **PNS Meeting Welcome Reception and Dinner**
(Hofkeller, Residenz)
**Morning**
08:00-16:00  Meeting Registration
09:00-17:15  SFB Symposium
12:00-23:00  Hotel Check-In

**Evening**
18:15  Buses to Concert
18:45-19:15  Concert
           Old University, Aula
20:00  Welcome Reception and Dinner
       Hokfeller, Residenz
Morning

07:30-08:30  Breakfast

Special Session
“Clinical neuropathies for basic scientists”
Presented by Michael E. Shy and Hugh J. Willison

08:30  Meeting Registration

09:00-09:10  Welcome Address
Presented by Eva L. Feldman and Klaus V. Toyka

09:10-09:40  Plenary Lecture 1
RETROGRADE SIGNALING IN AXONAL REGENERATION
Mike Fainzilber

09:40-10:40  Platform Session 1
“Axonal Neuropathies, Axonal Degeneration and Regeneration”
Chairs: Steven S. Scherer and Douglas W. Zochodne

10:40-11:00  Coffee Break

11:00-11:30  Plenary Lecture 2
PNS Presidential Lecture
DIABETIC NEUROPATHY: MECHANISMS TO MANAGEMENT
Eva L. Feldman

11:30-12:30  Platform Session 2
“Diabetic and Metabolic Neuropathies”
Chairs: Richard A.C. Hughes and A. Gordon Smith

*Posters to go up on Sunday morning at 07:30 and to remain up all day Sunday and Monday.
Afternoon
12:30-14:00  Lunch,
Poster Session 1*

See Program Pages 12-21

*(Posters from Session 2 also on display)*

12:30-13:30 PNS Board Meeting

14:00-14:30  Plenary Lecture 3
MECHANISMS OF ENHANCED SALTATORY CONDUCTION
IN MYELINATED FIBERS
Peter J. Brophy

14:30-15:30  Platform Session 3a
“Myelin and Demyelinating Neuropathies”
Chairs: Robert P. Lisak and Angelo E. Schenone

15:30-16:00  Coffee Break

16:00-17:30  Platform Session 3b
“My immune and Inflammatory Neuropathies”
Chairs: Patricia J. Armati and David R. Cornblath

Evening
17:30-18:30  General Membership Meeting

18:30-19:30  Posters

20:00  Dinner

21:00  Special Interest Groups
“Novel treatments for inflammatory neuropathies”
Presented by Eduardo Nobile-Orazio

“Neuropathic pain”
Presented by Giuseppe Lauria

“Nerve biopsy”
Presented by Angelo Quattrini and J. Michael Schröder
**Morning**

07:30-08:30 **Breakfast**

**Special Session**
“Career options in the field of peripheral nerve research”
Presented by Eva L. Feldman

09:00-09:30 **Plenary Lecture 4**
NERVE EXCITABILITY
Hugh Bostock

09:30-10:30 **Platform Session 4a**
“Painful Neuropathies, Ion Channels”
**Chairs:** Giuseppe Lauria and Claudia L. Sommer

10:30-11:00 **Coffee Break**

11:00-12:30 **Platform Session 4b**
“Immune and Inflammatory Neuropathies”
**Chairs:** Marinella Carpo and Hugh J. Willison

*Posters to go up on Sunday morning at 07:30 and to remain up all day Sunday and Monday.*
Afternoon 12:30-14:00
Lunch, Poster Session 2*
See Program Pages 26-35
(Posters from Session 1 also on display)

14:00 Free Afternoon
Old City Tour
or
Walk Through Würzburger Stein Vineyard
or
Museum of Modern Art Kulturspeicher
or
Shalom Europa Jewish Congregation and Museum

Evening 19:00
Dinner

20:30-21:30 Clinical Cases
“Genetics”
Presented by Mary M. Reilly and Davide Pareyson

“Inflammatory Neuropathies”
Presented by Jean-Marc Léger and Michael Lunn

“Diabetic and Metabolic Neuropathies”
Presented by James W. Russell and A. Gordon Smith
Morning
07:30-08:30  Breakfast

Special Session
“Basic science for clinicians”
Presented by Steven S. Scherer and Lawrence Wrabetz

09:00-09:30  Plenary Lecture 5
NEURON-GLIA SIGNALLING AND THE PROTECTION OF AXON FUNCTION BY SCHWANN CELLS
Klaus-Armin Nave

09:30-10:30  Platform Session 5a
“Axonal Protection, Neurobiology”
Chairs: Rhona Mirsky and Klaus V. Tokya

10:30-11:00  Coffee Break

11:00-12:30  Platform Session 5b
“Hereditary Neuropathies”
Chairs: Gian Maria Fabrizi and Pavel Seeman

*Posters to go up on Tuesday morning at 07:30 and to remain up all day Tuesday and Wednesday.
Afternoon
12:30-14:00  Lunch, Poster Session 3*
See Program Pages 38-47
(Posters from Session 4 also on display)
12:30-13:30 JPNS Editorial Board Meeting

14:00-14:30  Plenary Lecture 6
GENETIC NEUROPATHIES
Mary M. Reilly

14:30-15:30  Platform Session 6a
“Hereditary Neuropathies”
Chairs: Maria J. Saraiva and Vincent Timmerman

15:30-16:00  Coffee Break

16:00-17:00  Platform Session 6b
“Hereditary Neuropathies”
Chairs: Zarife Sahenk and Ueli Suter

Evening
17:00-17:45  Richard P. Bunge Memorial Lecture
AXON-SCHWANN CELL INTERACTIONS THAT PROMOTE MYELINATION
James. L. Salzer
Introduction by Mary B. Bunge

17:45-18:30  Posters

18:30  Buses to Farewell Banquet

19:00  PNS Farewell Banquet
(with music performance)
Morning
07:30-08:30  Breakfast
7:30-08:30 PNS New Board Meeting

09:00-09:30  Plenary Lecture 8
CRITICAL ROLE OF THE SirT2 DEACETYLASE IN PERIPHERAL NERVE MYELINATION
Jeffrey D. Milbrandt

09:30-10:30  Platform Session 7a
“Therapy”
Chairs: Masayuki Baba and Chiara Briani

10:30-11:00  Coffee Break

11:00-12:30  Platform Session 7b
“Diabetic and Metabolic Neuropathies”
Chairs: Rob Singleton and Anthony J. Windebank

Afternoon
12:30-12:40  Farewell Address

12:40-14:00  Lunch, Poster Session 4*
See Program Pages 52-61
(Posters from Session 3 also on display)

14:00  Departures

*Posters to go up on Tuesday morning at 07:30 and to remain up all day Tuesday and Wednesday.
<table>
<thead>
<tr>
<th>Time</th>
<th>Title/Author</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:30-08:30</td>
<td><strong>SPECIAL SESSION</strong>&lt;br&gt;CLINICAL NEUROPATHIES FOR BASIC SCIENTISTS&lt;br&gt;Michael E. Shy and Hugh J. Willison</td>
</tr>
<tr>
<td>09:00-09:10</td>
<td><strong>WELCOME ADDRESS</strong>&lt;br&gt;Eva L. Feldman and Klaus V. Tokya</td>
</tr>
<tr>
<td>09:10-09:40</td>
<td><strong>PLENARY LECTURE 1</strong>&lt;br&gt;RETROGRADE SIGNALING IN AXONAL REGENERATION&lt;br&gt;Mike Fainzilber</td>
</tr>
<tr>
<td>09:55-10:10</td>
<td>SCHWANN CELLS TRANSFER POLYRIBOSOMES TO REGENERATING AXONS&lt;br&gt;Court F, Hendriks W, Verheijen M, Midha R, van Minnen J</td>
</tr>
<tr>
<td>10:10-10:25</td>
<td>DIFFUSION TENSOR IMAGING (DTI) TO ASSESS AXONAL REGENERATION IN PERIPHERAL NERVES&lt;br&gt;Lehmann HC, Zhang J, Mori S, Sheikh KA</td>
</tr>
<tr>
<td>10:25-10:40</td>
<td>DIFFERENTIAL GENE EXPRESSION IN DENERVATED MOTOR AND SENSORY SCHWANN CELLS&lt;br&gt;Wright MC, Coppola G, Geschwind DH, Brushart TM, Höke A</td>
</tr>
</tbody>
</table>
**Plenary Lecture 2 and Platform Session 2**

Sunday, July 5, 2009  
11:00-12:30

“Diabetic and Metabolic Neuropathies”

**Chairs:** Richard A.C. Hughes and A. Gordon Smith

<table>
<thead>
<tr>
<th>Time</th>
<th>Title/Author</th>
</tr>
</thead>
</table>
| 11:00-11:30  | **PLENARY LECTURE 2**  
PNS Presidential Lecture  
DIABETIC NEUROPATHY: MECHANISMS TO MANAGEMENT  
Eva L. Feldman |
| 11:30-11:45  | EARLY DIABETIC NEUROPATHY IS CHARACTERIZED BY PROGRESSIVE SMALL FIBER LOSS  
Smith AG, Bragg E, Arsenault C, Burch A, Singleton JR |
| 11:45-12:00  | PGC-1α REGULATION OF MITOCHONDRIAL DEGENERATION IN DIABETIC NEUROPATHY  
| 12:00-12:15  | MITOCHONDRIAL RESPIRATORY CHAIN DYSFUNCTION OF LUMBAR DORSAL ROOT GANGLIA IN STREPTOZOTOCIN-INDUCED DIABETIC RATS AND ITS CORRECTION BY INSULIN TREATMENT  
Chowdhury SKR, Smith DR, Fernyhough P |
| 12:15-12:30  | PATHWAYS OF HYPERGLYCEMIA INDUCED NEUROTOXICITY  
Melli G, Taina M, Camozzi F, Podini P, Quattrini A, Lauria G |
<table>
<thead>
<tr>
<th>Poster</th>
<th>Title/Author</th>
</tr>
</thead>
</table>
| 1      | MITOFUSIN 2 INTERACTS WITH COMPONENTS OF THE MITOCHONDRIAL TRANSPORT APPARATUS AND IS ESSENTIAL FOR THE AXONAL TRANSPORT OF MITOCHONDRIA  
Misko A, Wegorzewska I, Milbrandt J, Baloh RH |
| 3      | ANALYSIS OF SMALL FIBRE FUNCTION IN THE C3 MOUSE, A MODEL OF CMT1A  
Clark AJ, AlQatari M, Shield K, Hantke J, Jessen KR, Koltzenburg M |
| 5      | EXPLORATION OF PATHOPHYSIOLOGICAL MECHANISMS IN CMT4H, AN AUTOSOMAL RECESSIVE DEMYELINATING FORM OF CHARCOT MARIE TOOTH DISEASE, CAUSED BY MUTATIONS IN FGD4, Encoding THE RHOGEF FRABIN  
Baudot C, Poitelon Y, Mégarbané A, Lévy N, Delague V |
| 7      | USEFULNESS OF COMBINED NERVE AND MUSCLE BIOPSY IN THE DIAGNOSIS OF AMYLOID NEUROPATHY. A STUDY OF SIX NEW CASES  
| 9      | AN ADULT ONSET CASE OF CHARCOT-MARIE-TOOTH DISEASE TYPE I WITH ARG381CYS IN EGR2 GENE MUTATION  
Lucchetta M, Taioli F, Briani C, Fabrizi G |
| 11     | PAIN AND SMALL FIBRE FUNCTION IN CMT 1A: PRELIMINARY RESULTS  
Laurà M, Hutton EJ, Morrow J, Blake J, Lunn MPT, Pareyson D, Koltzenburg M, Reilly MM |
| 13     | CARPAL TUNNEL SYNDROME IN CHARCOT-MARIE-TOOTH DISEASE TYPE 1  
O’Ferrall EK, Stewart JD, Chalk C |
| 15     | HAND DYSFUNCTION IS DETERMINED BY MOTOR AXON LOSS IN CHARCOT-MARIE-TOOTH DISEASE 1A  
Videler AJ, Beelen A, van Schaik IN, de Visser M, Nollet F |
<table>
<thead>
<tr>
<th>Poster</th>
<th>Title/Author</th>
</tr>
</thead>
</table>
| 17     | CMT1A IN CHILDREN - CLINICAL TESTING OF DISEASE SEVERITY AND PROGRESSION  
        Haberlová J, Seeman P |
| 19     | CLINICAL CHARACTERIZATION AND LINKAGE ANALYSIS OF A NOVEL X-LINKED DISTAL SPINAL MUSCULAR ATROPHY/HEREDITARY MOTOR NEUROPATHY SYNDROME  
| 21     | BEHAVIOURAL PROFILING OF A MOUSE MODEL OF CMT1A WITH 3 TO 4 COPIES OF PMP22  
        Hantke J, Wilton D, Latouche M, Baas F, Mirsky R, Jessen K |
| 23     | DEVELOPMENT OF A PERIPHERAL NEUROPATHY PROTEIN INTERACTION NETWORK  
        Srinivasan R, Jones E, Abraham JL, Suresh S, Svaren J |
| 25     | TRANSTHYRETIN AMYLOIDOSIS IN SOUTHERN ITALY POPULATION: DESCRIPTION OF A COHORT OF PATIENTS WITH PHE64LEU MUTATION AND LATE ONSET  
        Mazzeo A, Di Leo R, Russo M, Stancanelli C, Minutoli F, Di Bella G, Vita G |
| 27     | CHARCOT-MARIE-TOOTH DISEASE TYPE 1A DUPLICATION: REFINING THE MINIMAL ADULT PHENOTYPE  
        Berciano J, Gallardo E, García A, Ramón C, Mateo I, Infante J, Rodríguez-Rodríguez E, Combarros O |
| 29     | NOVEL GIANT AXONAL NEUROPATHY MUTATION C→A146{ALA49GLU} MIMICKING CHRONIC IMMUNE DEMYELINATING POLYRADICULONEUROPATHY  
        Figueroa JJ, Kuntz NL, Dyck PJ, Engelstad JK, Klein CJ |
| 31     | SMALL NERVE FIBER INVOLVEMENT IN PATIENTS WITH FABRY'S DISEASE  
        He L, Ueçeyler N, Breunig F, Sommer C |
<table>
<thead>
<tr>
<th>Poster</th>
<th>Title/Author</th>
</tr>
</thead>
<tbody>
<tr>
<td>33</td>
<td>CLINICAL AND SCHWANN CELL PHENOTYPES IN A PATIENT WITH PMP22 HOMOZYGOUS NULL MUTATION&lt;br&gt;<strong>Katona I</strong>, Saporta MA, Carr L, MacDonald F, Brueton L, Suter U, Shy ME, Reilly MM, Li J, Roper HP</td>
</tr>
<tr>
<td>37</td>
<td>CMT2A2 WITH UPPER MOTOR NEURON SIGNS IN A PATIENT WITH A NOVEL DE NOVO MUTATION IN MFN2&lt;br&gt;<strong>Ajroud-Driss S</strong>, Fecto F, Ajroud K, Yang Y, Donkervoort S, Siddique N, Siddique T</td>
</tr>
<tr>
<td>39</td>
<td>COMPARISON OF CLINICAL PHENOTYPE OF TRANSTHYRETIN VAL107 TO LATE ONSET MET30 FAMILIAL AMYLOID POLYNEUROPATHIES (FAP) IN FRANCE&lt;br&gt;<strong>Mariani L-L</strong>, Lozeron P, Lacroix C, Misrahi M, Adams D</td>
</tr>
<tr>
<td>41</td>
<td>MITOCHONDRIAL NEUROPATHY OF MNGIE&lt;br&gt;<strong>Gutmann L</strong>, Nance C</td>
</tr>
<tr>
<td>43</td>
<td>EFFECT OF ORAL CURCUMIN ON DÉJERINE-SOTTAS DISEASE&lt;br&gt;<strong>Burns J</strong>, Joseph PD, Rose KJ, Wicks SJ, Ryan MM, Ouvrier RA</td>
</tr>
<tr>
<td>45</td>
<td>CI-PERINOMS: CHEMOTHERAPY INDUCED-PERIPHERAL NEUROPATHY OUTCOME MEASURES STUDY&lt;br&gt;<strong>Cavaletti G</strong>; for the CI-PERINOMS Study Group</td>
</tr>
<tr>
<td>Poster</td>
<td>Title/Author</td>
</tr>
<tr>
<td>--------</td>
<td>-------------</td>
</tr>
</tbody>
</table>
| 49     | PROLONGED ADMINISTRATION OF HIGH DOSE ASCORBIC ACID IMPAIRS RAT SCIATIC NERVE FUNCTIONAL RECOVERY AFTER CRUSH INJURY  
**Wirguin I**, Bersudsky M |
| 51     | RANDOMISED TRIAL OF NIGHT CASTING FOR ANKLE CONTRACTURE IN CHILDREN WITH CHARCOT-MARIE-TOOTH DISEASE  
**Rose KJ**, Raymond J, Refshauge K, North KN, Burns J |
| 53     | TREATMENT OF PERIPHERAL NEUROPATHY ASSOCIATED WITH M-PROTEINEMIA  
**Kobayashi M**, Takeuchi M, Suzuki M, Yamane K, Ohashi T, Uchiyama S |
| 55     | FUNCTIONAL EFFECTS OF IGF-I DURING THE DIFFERENTIATION OF HUMAN SPINAL CORD STEM CELLS  
**Lunn JS**, Johe K, Feldman EL |
| 57     | A LANDMARK CLINICAL TRIAL OF A NOVEL SMALL MOLECULE TRANSTHYRETIN STABILIZER, FX-1006A, IN PATIENTS WITH TTR AMYLOID POLYNEUROPATHY: A PHASE II/III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY  
| 59     | MECHANISM OF AXONAL DEGENERATION IN PACLITAXEL INDUCED NEUROPATHY  
Clifford K, Melli G, Cavaletti G, Glass J, **Höke A** |
| 61     | DETECTION OF BRAIN PLASTICITY FOLLOWING PERIPHERAL NERVE INJURY USING fMRI  
**Pawela CP**, Hyde JS, Matthias H, Biswal B |
| 63     | EXPRESSION OF FGFs AND THEIR RECEPTORS IN MOUSE DORSAL ROOT GANGLIA  
**Battaloglu E**, Erkut C, Daglikoca D, Parman Y, Bugra K |
<table>
<thead>
<tr>
<th>Poster</th>
<th>Title/Author</th>
</tr>
</thead>
<tbody>
<tr>
<td>65</td>
<td>VARIATION OF THE NF-M KSP REPEAT SUB-DOMAIN AMONG MAMMALIAN SPECIES: IMPLICATIONS FOR ALTERING AXONAL STRUCTURE Barry DM, Eggert L, Schulz DJ, Garcia ML</td>
</tr>
<tr>
<td>67</td>
<td>SENSORIMOTOR ANALYSIS OF PERIPHERAL NERVE REGENERATION THROUGH T-TUBE CHAMBERS LOADED WITH NERVE GROWTH FACTOR (NGF) Kemp SWP, Webb AA, Midha R</td>
</tr>
<tr>
<td>69</td>
<td>HIGH-RESOLUTION ULTRASONOGRAPHY AS A PRE-OPERATIVE IMAGING TECHNIQUE FOR ULNAR NERVE SURGERY Ng Es, Vijayan J, Therimadasamy A, Chyan TT, Ng Ei, Wilder-Smith E</td>
</tr>
<tr>
<td>71</td>
<td>PIOGLITAZONE PROMOTES REMYELINATION AFTER CRUSH INJURY THROUGH CD36 Eto M, Sumi H, Fujimura H, Yoshikawa H, Sakoda S</td>
</tr>
<tr>
<td>73</td>
<td>SODIUM CHANNEL MODULATION IN AN ANIMAL MODEL OF PERIPHERAL NERVE DEMYELINATION Paul D, Dunne-Reilly AL, Gould HJ, England JD</td>
</tr>
<tr>
<td>75</td>
<td>DISTRIBUTION AND FUNCTION OF GALECTIN-1 AND GALECTIN-3 IN ADULT RAT DRG NEURONS Sango K, Yanagisawa H, Takaku S, Horie H, Kadoya T</td>
</tr>
<tr>
<td>77</td>
<td>THE MOLECULAR FUNCTION OF BEX-1 IN THE REGENERATION OF DEMYELINATED NEURONS IN THE PNS Khazaei MR, Halfter H, Young P</td>
</tr>
<tr>
<td>79</td>
<td>ELECTRICAL STIMULATION AUGMENTS PERIPHERAL NERVE REGENERATION THROUGH SCIATIC NERVE TRANSECTION INJURY GAPS Xu Q-G, Singh B, Gordon T, Midha R, Zochodne D</td>
</tr>
<tr>
<td>81</td>
<td>A NOVEL METHOD TO QUANTIFY CUTANEOUS SUDOMOTOR NERVE FIBERS: A CLINICAL PATHOLOGIC STUDY IN DIABETES Gibbons CH, Illigens BMW, Wang N, Freeman R</td>
</tr>
<tr>
<td>Poster</td>
<td>Title/Author</td>
</tr>
<tr>
<td>--------</td>
<td>-------------</td>
</tr>
</tbody>
</table>
| 83     | DEVELOPMENT OF AN AXONAL BIOMARKER FOR DIABETIC NEUROPATHY  
Krishnan AV, Lin C, Park S, Kiernan M |
| 85     | HIGH GLUCOSE INDUCES OXIDATIVE STRESS AND AXONOPATHY IN CULTURED ADULT SENSORY NEURONS DERIVED FROM DIABETIC RATS  
Zherebitskaya E, Akude E, Smith DR, Fernyhough P |
| 87     | CUTANEOUS INNERVATION AND LANGERHANS CELLS ARE REDUCED BY DIABETES AND ESTROGEN IN STREPTOZOTOCIN-TREATED RATS  
Doss ALN, Smith PG |
| 89     | NERVE CONDUCTION STUDIES ALONE ARE NOT AS ACCURATE AS NERVE CONDUCTION STUDIES AND ELECTROMYOGRAPHY IN DIAGNOSING DISORDERS OF PERIPHERAL NERVE  
| 91     | RELATIONSHIP BETWEEN HEAT-INDUCED VASOMOTION CHANGES AND INTRAEPIDERMAL NERVE FIBER DENSITY (IENFD) IN DIABETIC SMALL FIBER NEUROPATHY  
Nascimbene C, Barrella M, Osio M, Bana C, Vanotti A, Mariani C |
| 93     | ISCHAEMIC SUSCEPTIBILITY IN HYPERTENSIVE NERVE  
Nukada H, Baba M, Ogasawara S, McMorran PD, Yagihashi S |
| 95     | SKIN BIOPSY AND QUANTITATIVE SENSORY TESTING IN ASSESSMENT OF SMALL FIBER INVOLVEMENT IN PATIENTS WITH DIFFERENT CAUSES OF POLYNEUROPATHY  
Nebuchennykh M, Løseth S, Lindal S, Mellgren SI |
| 97     | CHARACTERIZATION OF THE MORPHOLOGICAL AND MOLECULAR CHANGES ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY IN TYPE 2 DIABETES  
Zenker J, de Preux Charles A-S, Arnaud E, Médard J-J, Chrast R |
<table>
<thead>
<tr>
<th>Poster</th>
<th>Title/Author</th>
</tr>
</thead>
</table>
| 99     | MYOCARDIAL SYMPATHETIC INNERVATION IN PATIENTS WITH PAINFUL SMALL FIBER POLYNEUROPATHY WITH IMPAIRED GLUCOSE TOLERANCE  
**Nascimento OJM**, Azevedo J, de Freitas MRG, Quintanilha G, Pupe C, Coutinho B, Orsini M |
| 101    | LONG-TERM FOLLOW-UP OF PROXIMAL DIABETIC NEUROPATHY IN A COHORT OF 16 PATIENTS  
**Amador M**, Lozeron P, Lacroix C, Théaudin M, Adams D |
| 103    | EVALUATION OF THE CONTINUOUS BUPRENORPHINE DELIVERY ANALGESIC EFFECT IN AN EXPERIMENTAL RAT MODEL OF PAINFUL DIABETIC NEUROPATHY  
| 105    | NEUROLOGICAL FOLLOW-UP IN PATIENTS AFTER DOMINO-LIVER TRANSPLANTATION  
| 107    | DOES ULNAR NERVE IMPAIRMENT AT THE WRIST CONTRIBUTE TO EXTRAMEDIAN SPREAD OF SENSORY SYMPTOMS IN CARPAL TUNNEL SYNDROME?  
**Tamburin S**, Cacciatori C, Praitano ML, Fiaschi A, Marani S, Zanette G |
| 109    | DIAGNOSTIC VALUE OF SKIN PUNCH BIOPSY IN NON-SYSTEMIC VASCULITIC PERIPHERAL NEUROPATHY  
**Üçeyler N**, Devigili G, Toyka KV, Sommer C |
| 111    | EFFECTS OF IMMUNOTHERAPY ON NERVE EXCITABILITY IN PATIENTS WITH CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY  
**Lin CS-Y**, Krishnan AV, Park SB, Kiernan MC |
| 113    | MAKING THE MOST OF ONLS DATA: CAN WE GET MORE OUT OF WHAT WE PUT IN?  
**Pace AA**, Hughes RAC, van Schaik IN, Hobart JC; for the RMC Trial Group |
<table>
<thead>
<tr>
<th>Poster</th>
<th>Title/Author</th>
</tr>
</thead>
</table>
| 115    | CLINICOPATHOLOGICAL FEATURES OF ACUTE AUTONOMIC AND SENSORY NEUROPATHY  
| 117    | THE ROLE OF TUMOR NECROSIS FACTOR ALPHA AS A MARKER IN CHRONIC INFLAMMATORY DEMYLELINATING POLYRADICULONEUROPATHY  
El-Etribi MA, Mohamed SA, El-Hefnawy NG, El-Wahab Reda RA, El-Maguid Shaheen HA, El-Mously SM |
| 119    | A RASCH-BUILT, LINEARLY-WEIGHTED OVERALL DISABILITY SUMSCORE FOR IMMUNE-MEDIATED PERIPHERAL NEUROPATHIES  
van Nes S, Faber C, Hermans M, Bakkers M, Kuitwaard K, van Doorn PA, Merkies ISJ; on behalf of the PeriNomS study group |
| 121    | CHRONIC DEMYLELINATING POLYNEUROPATHY (CIDP) AND RELAPSING REMITTING CENTRAL DEMYELINATION: SPREADING AUTOIMMUNITY FROM PERIPHERAL TO CENTRAL MYELIN?  
Ariatti A, Sola P, Girolami F, Canali E, Galassi G |
| 123    | ACUTE BRACHIAL DIPLEGIA DUE TO NEUROBORRELIOSIS  
Gorson KC, Marks D, Kolb D, Hayes M |
| 125    | THE CONTRIBUTION OF SALIVARY GLAND BIOPSY IN THE WORK-UP OF PATIENTS PRESENTING WITH A SMALL FIBER POLYNEUROPATHY  
Barboi A, Komorowski R, Jaradeh S, Prieto T, Yellick M, Fabian N, Dennis C, Esselman A |
| 127    | NO ASSOCIATION BETWEEN GUILLAIN-BARRÉ SYNDROME AND DENGUE FEVER  
Santos J, Marques W Jr, Fazan V, Barreira AA |
| 129    | MULTIFOCAL MOTOR NEUROPATHY IN GENETICALLY CONFIRMED CMT1A  
Gallia F, Bossi B, Terenghi F, Nobile-Orazio E |
<table>
<thead>
<tr>
<th>Poster</th>
<th>Title/Author</th>
</tr>
</thead>
</table>
| 131    | INNATE ACTIVITY OF THE MANNAN BINDING LECTIN PATHWAY IS A DISEASE MODIFYING FACTOR IN IGM GAMMOPATHY ASSOCIATED POLYNEUROPATHY  
Stork ACJ, Notermans NC, van Strijp J, Heezius HCJM, van den Berg LH, van der Pol W-L |
| 133    | ANTIBODIES AGAINST AXO-GIAL PROTEINS AT NODES OF RANVIER IN GUILAIN-BARRÉ SYNDROME  
Zhang G, Manoharan S, Sheikh KA |
| 135    | PROSPECTIVE COHORT STUDY OF 140 PATIENTS WITH IgM MGUS POLYNEUROPATHY: DEVELOPMENT OF A PROGNOSTIC MODEL  
Niermeijer JMF, Fischer K, Eurelings M, Franssen H, Wokke JHJ, Notermans N |
| 137    | FATAL MULTIFOCAL MOTOR NEUROPATHY (MMN)  
| 139    | A NECROTIZING ARTERITIS EVOLVING FOR 14 YEARS MIMICKING A WARTENBERG-LIKE SYNDROME  
Cassereau J, Baguenier-Desormeaux C, Letournel F, Dubas F, Nicolas G |
| 141    | ANTI-αB-CRYSTALLIN IMMUNOREACTIVITY IN GUILAIN-BARRÉ SYNDROME AND CHRONIC INFLAMMATORY Demyelinating POLYNEUROPATHY  
Hegen H, Reindl M, Wanschitz J, Ehling R, Berger T, Deisenhammer F, Rainer C |
| 143    | ELECTROPHYSIOLOGICAL CHARACTERISTICS IN RELATION TO INFECTIONS IN GUILAIN-BARRÉ SYNDROME  
Drenthen J, Blok JH, Meulstee J, Maathuis EM, van Doorn PA, Visser GH, Jacobs BC |
| 145    | EFFICIENCY OF COMPLEMENT ACTIVATION BY GQ1b-SPECIFIC ANTIBODIES DETERMINES CLINICAL PRESENTATIONS, FISHER SYNDROME, BICKERSTAFF BRAINSTEM ENCEPHALITIS, OR ACUTE OPHTHALMOPARESIS WITHOUT ATAXIA  
Odaka M, Hirata K, Yuki N |
<table>
<thead>
<tr>
<th>Poster</th>
<th>Title/Author</th>
</tr>
</thead>
</table>
| 147    | IMMUNE-MEDIATED POSTSURGICAL NEUROPATHY  
Staff NP, Engelstad JK, Dyck PJ, **Dyck PJB** |
| 149    | DELAYED FACIAL DIPLEGIA IN GUILAIN-BARRÉ AND FISHER SYNDROMES  
**Tatsumoto M**, Hirata K, Yuki N |
| 151    | INFLAMMATORY MULTIFOCAL ENCEPHALOMYELOPOLYRADICULONEUROPATHY MIMICKING A GRANULOMATOUS OR LYMPHOMATOUS PROCESS  
**Sandroni P**, Milone M, Uhm JH, Scheithauer B |
| 153    | INTRAOPERATIVE ON-NERVE NERVE CONDUCTION STUDY AND CONVERSION FACTOR IN THE SURAL NERVE  
**Oh SJ**, Hemmi S, Kurokawa K, Hatanaka Y |
| 155    | MORPHOLOGICAL EVOLUTION OF DEMYELINATION IN IGM-MGUS ANTI-MAG ASSOCIATED NEUROPATHY  
<table>
<thead>
<tr>
<th>Time</th>
<th>Title/Author</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00-14:30</td>
<td><strong>PLENARY LECTURE 3</strong>&lt;br&gt;MECHANISMS OF ENHANCED SALTATORY CONDUCTION IN MYELINATED FIBERS&lt;br&gt;<em>Peter J. Brophy</em></td>
</tr>
<tr>
<td>14:45-15:00</td>
<td>THE ROLE OF LGI4 AND ADAM22 IN PERIPHERAL NERVE DEVELOPMENT&lt;br&gt;<em>Ozkaynak E, Abello G, Driegen S, Jaegle M, van Berge L, Bermingham J, Sagane K, Meijer D</em></td>
</tr>
<tr>
<td>15:15-15:30</td>
<td>MANIPULATION OF THE PI3-K PATHWAY IN PERIPHERAL NEURONS THROUGH PTEN INHIBITION ENHANCES AXON OUTGROWTH&lt;br&gt;<em>Christie KJ, Webber CA, Martinez JA, Zochodne DW</em></td>
</tr>
</tbody>
</table>
Sunday, July 5, 2009  16:00-17:30

“Immune and Inflammatory Neuropathies”

**Chairs:** Patricia J. Armatti and David R. Cornblath

<table>
<thead>
<tr>
<th>Time</th>
<th>Title/Author</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:00-16:15</td>
<td>CLINICAL SPECTRUM AND CORRELATES OF OUTCOME IN 88 PATIENTS WITH MULTIFOCAL MOTOR NEUROPATHY <strong>Cats EA</strong>, van der Pol W-L, Piepers S, Veldink JH, van den Berg-Vos RM, Jacobs BC, Franssen H, van den Berg LH</td>
</tr>
<tr>
<td>16:15-16:30</td>
<td>ANTI-GANGLIOSIDE ANTIBODY-MEDIATED NODAL DISRUPTION IN MOTOR AND SENSORY NERVE FIBERS Funakoshi K, Schafer DP, Rasband MN, Hirata K, Yuki N, <strong>Susuki K</strong></td>
</tr>
<tr>
<td>16:45-17:00</td>
<td>DEVELOPING PROGNOSTIC MODELS FOR GUILLAIN-BARRÉ SYNDROME: DESIGN OF A PROSPECTIVE INTERNATIONAL STUDY <strong>Jacobs BC</strong>, Steyerberg EW, van Doorn PA, Cornblath DR, Hughes RAC; for the Inflammatory Neuropathy Consortium (INC)</td>
</tr>
<tr>
<td>17:00-17:15</td>
<td>ACUTE ATAXIC NEUROPATHY WITHOUT ATAXIA <strong>Ito M</strong>, Hirata K, <strong>Yuki N</strong></td>
</tr>
<tr>
<td>Time</td>
<td>Title/Author</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
</tbody>
</table>
| 07:30-08:30  | **SPECIAL SESSION**  
CAREER OPTIONS IN THE FIELD OF PERIPHERAL NERVE RESEARCH  
Eva L. Feldman |
| 09:00-09:30  | **PLENARY LECTURE 4**  
NERVE EXCITABILITY  
Hugh Bostock |
| 09:30-09:45  | A SHED FORM OF LDL RECEPTOR-RELATED PROTEIN-1 INHIBITS MECHANICAL HYPERALGESIA AND PAIN RELATED CELL SIGNALING AFTER PERIPHERAL NERVE INJURY  
| 09:45-10:00  | SKIN INNERVATION AND CLINICAL SYMPTOMS IN GUILLAIN-BARRÉ SYNDROME  
Ruts L, van Doorn PA, Lauria G |
| 10:00-10:15  | TWO DISTINCT AXOGLIAL ADHESION SYSTEMS ASSEMBLE PNS NODES OF RANVIER  
| 10:15-10:30  | DETERMINATION OF ACTION POTENTIAL INITIATION SITES IN UNMYELINATED SENSORY NERVE TERMINALS  
Carr RW, Brock JA |
### Time | Title/Author
---|---
11:00-11:15 | CLINICAL FEATURES OF GUILLAIN-BARRÉ SYNDROME WITH ANTI-GD1A/GD1B IGG ANTIBODIES  
**Kusunoki S**, Kanata A, Kaida K

11:15-11:30 | CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY (CIDP) TREATMENT WITH IMMUNE GLOBULIN INTRAVENOUS, 10% CAPRYLATE/CHROMATOGRAPHY PURIFIED (IGIV-C) IN A RANDOMIZED, PLACEBO-CONTROLLED TRIAL: A SUMMARY OF THE ICE STUDY  
**Hughes RAC**, Bril V, Dalakas MC, Deng C, Donofrio P, Hanna K, Hartung H-P, Latov N, Merkies ISJ, van Doorn PA; on behalf of the ICE Study Group

11:30-11:45 | Fc GAMMA RECEPTORS (FcγR) ON INJURED SCHWANN CELLS FACILITATE ANTIBODY-MEDIATED MODULATION OF AXON REGENERATION  
**Sheikh KA**, Zhang G, Lehmann H

11:45-12:00 | GBS-ASSOCIATED CAMPYLOBACTER LOS ACTIVATES DENDRITIC CELLS TO PRODUCE B-CELL PROLIFERATING FACTORS VIA TOLL-LIKE RECEPTOR-4  
**Huibinga R**, Kuijff ML, van Rijs W, Bax M, van Kooyk Y, Nieuwenhuis EES, Samsom JN, Jacobs BC

12:00-12:15 | IVIg INHIBITS THE CLASSICAL COMPLEMENT PATHWAY AND DECREASES DEPOSITION OF COMPLEMENT IN MULTIFOCAL MOTOR NEUROPATHY  
**Piepers S**, Jansen MD, Cats EA, van Sorge NM, van den Berg LH, van der Pol W-L

12:15-12:30 | TLR EXPRESSION IN THE PERIPHERAL NERVE  
Van Avondt K, Goethals S, Jacobs A, Timmerman C, **Janssens S**
<table>
<thead>
<tr>
<th>Poster</th>
<th>Title/Author</th>
</tr>
</thead>
</table>
| 2      | DIAGNOSTIC VALUE OF HIGH-RESOLUTION SONOGRAPHY VERSUS ELECTROMYOGRAPHY IN CHILDREN AND JUVENILES WITH CHARCOT-MARIE-TOOTH DISEASE 1A  
**Borchert A**, Schwartz O, Kurlemann G, Young P, Schilling M |
| 4      | ALS AND HNPP: A NEW CASE  
**Conte A**, Luigetti M, Madia F, Del Grande A, Zollino M, Tonali PA, Sabatelli M |
| 6      | COMPLEMENT FACTOR H AND HNPP  
| 8      | COMPARISON OF ENDOCYTOSIS IN DYNAMIN 2 MUTATIONS PRODUCING NEUROPATHY AND IN MUTATIONS CAUSING MYOPATHY  
| 10     | PROXIMAL COMPENSATION FOR DISTAL WEAKNESS: COMPARISON OF SUBJECTS WITH CHARCOT-MARIE-TOOTH DISEASE AND HEALTHY SUBJECTS WITH EXERCISE INDUCED WEAKNESS  
**Ramdharry GM**, Day BL, Reilly MM, Marsden JF |
| 12     | CHOP DELETION DOES NOT MITIGATE THE PHENOTYPE OF THE P0 R98C MOUSE MODEL OF EARLY-ONSET CMT 1B  
| 14     | DESCRIPTION OF SIX PATIENTS WITH CHARCOT-MARIE-TOOTH TYPE 4C AND NOVEL CLINICAL FEATURES  
**Dubourg O**, Stojkovic T, Poirier K, Tardieu S, Le Guern E |
| 16     | SKIN BIOPSY IN ANIMAL MODELS OF HEREDITARY NEUROPATHIES  
<table>
<thead>
<tr>
<th>Poster</th>
<th>Title/Author</th>
</tr>
</thead>
</table>
| 18     | HEREDITARY MOTOR AND SENSORY NEUROPATHY TYPE LOM (CMT4D) IN TWO CZECH GYPSY FAMILIES  
| 20     | NEUROLOGICAL FEATURES IN ADULT TRIPLE A (ALLGROVE) SYNDROME  
| 22     | CHARACTERISATION OF SH3TC2, A PROTEIN ASSOCIATED WITH CHARCOT-MARIE-TOOTH DISEASE TYPE 4C  
| 24     | NEUROFILAMENTS ARE REQUIRED FOR THE MAINTENANCE OF MYELINATED AXONS: ANALYSIS OF A HOMOZYGOUS MUTATION IN NEFL ASSOCIATED WITH AN EARLY ONSET CHARCOT-MARIE-TOOTH DISEASE  
Yum SW, Zhang J, Mo K, Li J, Scherer SS |
| 26     | EARLY ONSET NEUROPATHY OF MITOCHONDRIAL NEUROGASTROINTESTINAL ENCEPHALOMYOPATHY MIMICKING CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY IN CHILDHOOD  
| 28     | FREQUENCY OF CHARCOT-MARIE-TOOTH (CMT) SUBTYPES IN PATIENTS EVALUATED AT WAYNE STATE UNIVERSITY  
Sottile SL, Miller LJ, Feely SME, Shy ME, Siskind CE |
| 30     | MOLECULAR DEFECTS IN PATIENTS AFFECTED BY DISTAL HEREDITARY MOTOR NEUROPATHY OR ‘SPINAL’ FORM OF CHARCOT-MARIE-TOOTH DISEASE  
<table>
<thead>
<tr>
<th>Poster</th>
<th>Title/Author</th>
</tr>
</thead>
</table>
| 32     | AXONAL EXCITABILITY CHANGES IN GENETIC NEURONAL ION CHANNEL DISORDERS  
Tomlinson SE, Tan SV, Kullmann DM, Burke D, Hanna MG, Bostock H |
| 34     | SYRINGOMYELIA-LIKE PHENOTYPE OF TANGIER DISEASE: CLINICAL, ELECTROPHYSIOLOGICAL AND GENETIC FINDINGS  
| 36     | EFFECT OF LIVER TRANSPLANTATION ON THE SURVIVAL OF PATIENTS WITH FAMILIAL AMYLOID POLYNEUROPATHY  
| 38     | THAOS - TRANSTHYRETIN AMYLOIDOSIS OUTCOMES SURVEY, A NEW GLOBAL, WEB-BASED REGISTRY  
| 40     | INCREASING THE DIFFERENTIAL DIAGNOSIS OF THE INHERITED Demyelinating Neuropathies WITH NON-UNIFORM NERVE CONDUCTION (NCS): ANDERMANN SYNDROME  
Marques W Jr, Lourenço CM, Marques VD, Gonçalves MV, Sobreira C, Barreira AA |
| 42     | EVOLUTION OF FOOT AND ANKLE MANIFESTATIONS IN CHILDHOOD CMT1A  
Burns J, Ryan MM, Ouvrier RA |
| 44     | ORAL HIGH DOSE ASCORBIC ACID TREATMENT FOR ONE YEAR DID NOT IMPROVE MYELINATION IN YOUNG CMT1A PATIENTS: A PROOF OF PRINCIPLE PILOT STUDY  
Verhamme C, de Haan RJ, Vermeulen M, Baas F, de Visser M, van Schaik IN |
<table>
<thead>
<tr>
<th>Poster</th>
<th>Title/Author</th>
</tr>
</thead>
<tbody>
<tr>
<td>48</td>
<td>ALEMTUZUMAB IN THE TREATMENT OF IVIg-DEPENDENT CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY <strong>Llewelyn JG</strong>, Reilly MM, Krishnan A, Doran M, Ryan A, Robertson NP</td>
</tr>
<tr>
<td>50</td>
<td>A PLACEBO-CONTROLLED TRIAL OF RITUXIMAB IN IgM ANTIMAG ANTIBODY DEMYELINATING NEUROPATHY <strong>Dalakas MC</strong>, Rakocevic G, Salajegheh M, Dambrosia JM, Hahn AF, Raju R, McElroy B</td>
</tr>
<tr>
<td>52</td>
<td>RITUXIMAB USAGE IN CIDP: A RETROSPECTIVE E-MAIL BASED DATA COLLECTION <strong>Lunn MP</strong>; for the Inflammatory Neuropathy Consortium</td>
</tr>
<tr>
<td>54</td>
<td>THE POTASSIUM CHANNEL ACTIVATOR FLUPIRTINE AFFECTS MULTIPLE EXCITABILITY PARAMETERS OF PERIPHERAL MYELINATED AXONS <strong>Grafe P</strong>, Carr RW, Schwarz JF</td>
</tr>
<tr>
<td>56</td>
<td>MECHANISMS OF IGF-I NEUROPROTECTION AGAINST MOTOR NEURON DEGENERATION <strong>Sakowski SA</strong>, Busta AS, Dowling JJ, Feldman EL</td>
</tr>
<tr>
<td>58</td>
<td>A COMPARISON STUDY OF DROP FOOT BETWEEN COMMON PERONEAL NEUROPATHY AND LUMBAR SPINE DISORDERS TO FIND DISTINCT CATEGORIES <strong>Sekiguchi Y</strong>, Kikuchi S, Konno S, Sekiguchi M</td>
</tr>
<tr>
<td>60</td>
<td>CENTRAL CONDUCTION TIMES IN PATIENTS WITH SUBACUTE MYELO-OPTICO-NEUROPATHY BY MAGNETIC STIMULATION <strong>Matsumoto A</strong>, Tajima Y, Sasaki H</td>
</tr>
<tr>
<td>Poster</td>
<td>Title/Author</td>
</tr>
<tr>
<td>--------</td>
<td>-------------</td>
</tr>
</tbody>
</table>
| 62     | TOPOGRAPHICAL DISTRIBUTION OF MOTOR FASCICLES IN THE TIBIAL NERVE OF THE RAT  
  **Pascual-Font A**, Badia J, Udina E, Navarro X |
| 64     | EVIDENCE THAT NETRIN-DCC INTERACTIONS ARE INVOLVED IN PERIPHERAL NERVE REGENERATION  
  **Webber CA**, Christie KJ, Cheng C, Martinez JA, Thomas DA, Zochodne DW |
| 66     | CAN CUTANEOUS INNERVATION DIFFERENTIATE PARKINSON’S DISEASE FROM MULTIPLE SYSTEM ATROPHY?  
| 68     | ROLE OF SCHWANN CELL DYSTROGLYCAN IN THE ARCHITECTURE OF NODES OF RANVIER  
  **Colombelli C**, Zambroni D, Occhi S, Wrabetz L, Feltri ML |
| 70     | PRELIMINARY VALIDATION OF SLICK-A MICE AS A TOOL FOR ADULT INDUCIBLE CRE-RECOMBINASE MEDIATED GENETIC MANIPULATION IN REGENERATING PERIPHERAL NEURONS  
  **Fricker F**, Lago N, Jenkins M, McMahon S, Bennett D |
| 72     | A NEW MODEL FOR CISPLATIN INDUCED PERIPHERAL NEUROPATHY  
  **Froemel D**, Podratz JL, Tang A, Windebank AJ |
| 74     | LAMININ PRODUCES SUPERIOR DRG NEURITE OUTGROWTH ON ALIGNED NANOFIBERS WHEN SCHWANN CELLS ARE IMPAIRED BY APHIDICOLIN  
  **Corey JM**, Leach MK, Regan T, Khanna S, Gertz C, Chacon-Saavedra A, Martin DC, Feldman EL |
| 76     | A COMBINATORIAL GLYCOLUMIDOMIC APPROACH TO THE IDENTIFICATION OF NEW MOLECULAR TARGETS IN GUILLAIN-BARRÉ SYNDROME  
<table>
<thead>
<tr>
<th>Poster</th>
<th>Title/Author</th>
</tr>
</thead>
<tbody>
<tr>
<td>78</td>
<td>VALIDATION OF A LONG PERIPHERAL NERVE GRAFT MODEL IN THE SHEEP FORELIMB Forden J, Xu Q-G, Walsh S, <strong>Midha R</strong></td>
</tr>
<tr>
<td>82</td>
<td>MORPHO-FUNCTIONAL STUDY OF SINGLE SWEAT GLANDS IN FIVE PATIENTS WITH ANHIDROSIS <strong>Provitera V</strong>, Nolano M, Stancanelli A, Caporaso G, Santoro L</td>
</tr>
<tr>
<td>84</td>
<td>PERIPHERAL NERVE FUNCTION IN PATIENTS WITH CLINICAL EVIDENCE OF DIABETIC NEUROPATHY <strong>Gibbons CH</strong>, Freeman R, Veves A</td>
</tr>
<tr>
<td>86</td>
<td>REVERSAL OF PERIPHERAL NEUROPATHY BY AN MGLUR3 AGONIST IN AN ANIMAL MODEL OF IGT AND OBESITY Muragundla A, Anderson A, Koch LG, Britton SL, <strong>Russell JW</strong></td>
</tr>
<tr>
<td>88</td>
<td>BENEFICIAL EFFECTS OF EXERCISE ON DIABETIC NEUROPATHY Kluding P, Pasnoor M, Rupali R, Tseng B, Moses R, Herbelin L, Farmer K, Jernigan S, <strong>Wright D</strong></td>
</tr>
<tr>
<td>90</td>
<td>PAINFUL DIABETIC NEUROPATHY AFTER STRICT GLYCEMIC CONTROL. A NOT-SO-RARE EVENT? <strong>Brindani F</strong>, Vitetta F, Desimoni M, Giovanelli M, Marbini A, Gemignani F</td>
</tr>
<tr>
<td>92</td>
<td>THE EFFECT OF LONG-TERM ETHANOL INGESTION ON PERIPHERAL NERVES IN RATS Imai T, Amari M, <strong>Fujioka T</strong></td>
</tr>
<tr>
<td>94</td>
<td>EFFECT OF AGE AND SEX ON POWER SPECTRAL ANALYSIS OF HEART RATE VARIABILITY IN HEALTHY SUBJECTS AND SOURCES OF VARIABILITY <strong>Bednarik J</strong>, Vickova-Moravcova E, Micakova L, Bursova S</td>
</tr>
<tr>
<td>Poster</td>
<td>Title/Author</td>
</tr>
<tr>
<td>--------</td>
<td>-------------</td>
</tr>
</tbody>
</table>
| 96     | BEST TEST? COMPARISON OF DISTAL-LEG SKIN BIOPSY, AUTONOMIC FUNCTION TESTING, BLOOD-FLOW, AND AXON FLARE MEASUREMENTS FOR DIAGNOSIS OF SMALL-FIBER POLYNEUROPATHY (SFPN)  
_Klein MM_, Downs HM, Oaklander AL |
| 98     | REGULATION OF NAV1.7 IN PAINFUL DIABETIC NEUROPATHY BY GPCR ACTIVATION  
_Chattopadhyay M_, Maier K, Mata M, Fink DJ |
| 100    | SMALL DIAMETER DRG NEURONS EXHIBIT INCREASED LOW-VOLTAGE ACTIVATED T-TYPE CALCIUM CURRENTS IN EXPERIMENTAL DIABETIC NEUROPATHY  
_Shankarappa SA_, Piedras-Renterà ES, Stubbs EB Jr |
| 102    | BEHAVIOURAL AND MORPHOLOGICAL DESCRIPTION OF BORTEZOMIB-INDUCED PAINFUL NEUROPATHY IN RATS  
| 104    | ACUTE AND CHRONIC PAIN IN GUILLAIN-BARRÉ SYNDROME  
_Ruts L_, van Doorn PA; for the Dutch GBS study group |
| 106    | MYRICETIN MODULATES VOLTAGE ACTIVATED CALCIUM AND POTASSIUM CHANNEL CURRENTS IN SENSORY NEURONS OF RAT  
_Hagenacker T_, Hillebrandt I, Büsselberg D, Schäfers M |
| 108    | INITIAL CHARACTERIZATION OF ACQUIRED JUVENILE-ONSET SMALL-FIBER POLYNEUROPATHY (SFPN): EVIDENCE FOR ORGAN-SPECIFIC AUTOIMMUNITY  
_Oaklander AL |
| 110    | CLINICAL FEATURES OF PERIPHERAL NEUROPATHY IN PRIMARY SJÖGREN’S SYNDROME: A STUDY OF 25 CASES  
_Nascimento OJM_, Leijoto C, Quintanilha G, De Freitas MRG, Pupe C, Coutinho B |
<table>
<thead>
<tr>
<th>Poster</th>
<th>Title/Author</th>
</tr>
</thead>
</table>
| 112    | MULTIFOCAL MOTOR NEUROPATHY: A RETROSPECTIVE STUDY OF SENSORY NERVE CONDUCTION VELOCITIES IN LONG-TERM FOLLOW-UP OF 21 PATIENTS  
*Lievens I,* Fournier E, Viala K, Maisonobe T, Bouche P, Léger JM |
| 114    | NONSYSTEMIC VASCULITIC NEUROPATHY IN A 16-YEAR-OLD FEMALE  
*Callaghan BC,* Feldman EL, Dowling J |
| 116    | COINCIDENT CHRONIC AXONAL POLYNEUROPATHY AND NEUROMUSCULAR JUNCTION DISORDER: COINCIDENCE OR COMMON CAUSALITY?  
*Canali E,* Ariatti A, Girolami F, Valzania F, Galassi G |
| 118    | THE ROLE OF MATRIX METALLOPROTEINASE 9 IN CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY  
El-Etribi MA, Mohamed SA, El-Hefnawy NG, El-Wahab Reda RA, El-Maguid Shaheen HA, *El-Mously SM* |
| 120    | THE ROLE OF ACTIVITY DEPENDENT CONDUCTION BLOCK IN MMN AND CIDP  
*Straver DCG,* van den Berg LH, van den Berg-Vos RM, Franssen H |
| 122    | MEMBRANE ATTACK COMPLEX OF COMPLEMENT IS NOT ESSENTIAL FOR IMMUNE MEDIATED DEMYELINATION BUT IS ASSOCIATED WITH REDUCED TH17  
*Tran GT,* Hodgkinson SJ, Carter NM, Killingsworth M, Nomura M, Verma ND, Plain KM, Boyd R, Hall BM |
| 124    | ULTRASOUND VISUALIZATION OF CONDUCTION BLOCKS IN A CIDP PATIENT  
*Granata G,* Caliandro P, Pazzaglia C, Padua L |
| 126    | MBL COMPLEMENT PATHWAY ACTIVITY IS INCREASED IN PATIENTS WITH MULTIFOCAL MOTOR NEUROPATHY  
*Cats EA,* Van den Berg LH, van Strijp JA, Heezius EC, Rijkers GT, Piepers S, van der Pol W-L |
<table>
<thead>
<tr>
<th>Poster</th>
<th>Title/Author</th>
</tr>
</thead>
</table>
| 128    | ANTI-GANGLIOSIDE ANTIBODIES INDUCE AXONAL CONDUCTION FAILURE  
        David M, Pollard JD, Zhang G, Armati PJ, Sheikh K, Spies J |
| 130    | RELATIONSHIP OF ANTI-GANGLIOSIDE COMPLEX ANTIBODIES WITH CLINICAL PHENOTYPES IN ANTI-GQ1B IGG ANTIBODY SYNDROME  
        Funakoshi K, Ito M, Koike S, Hirata K, Yuki N |
| 132    | RADICULOPATHY REVEALING A NECROTIZING VASCULITIS IN ELEVEN NON-DIABETIC PATIENTS  
        Lozeron P, Michon M, Lacroix C, Theaudin M, Adams D |
| 136    | ECONOMIC COSTS OF CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY, MULTIFOCAL MOTOR NEUROPATHY AND PARAPROTEINAEMIC DEMYELINATING NEUROPATHY  
        Mahdi-Rogers M, Hughes RAC, McCrone P |
| 138    | RESPIRATORY FAILURE IN CIDP  
        Kamijo M, Shimono T, Yoko T, Umemura T, Sakakibara T |
| 140    | AFFINITY AND SPECIFICITY OF ANTI-GM1 ANTIBODIES IN THE EXPERIMENTAL AXONAL MODEL OF GUILLAIN-BARRÉ SYNDROME  
        Notturno F, Del Boccio P, Pieragostino D, Uncini A |
| 142    | PHARMACOKINETICS OF INTRAVENOUS IMMUNOGLOBULIN AND OUTCOME IN GUILLAIN-BARRÉ SYNDROME  
| 144    | ANTI-PERIPHERAL NERVOUS SYSTEM IMMUNOREACTIVITY IN PATIENTS WITH POSSIBLY PARANEOPLASTIC PERIPHERAL NEUROPATHY AND CANCER  
<table>
<thead>
<tr>
<th>Poster</th>
<th>Title/Author</th>
</tr>
</thead>
<tbody>
<tr>
<td>146</td>
<td>CLINICAL AND ELECTROPHYSIOLOGICAL OUTCOMES SHOW IMPROVEMENT OF THE POLYRADICULONEUROPATHY OCCURRING IN PORK PROCESSING WORKERS <em>Dyck PJB</em>, Tracy JA, Norell JE, Engelstad JK, Lachance DH</td>
</tr>
<tr>
<td>148</td>
<td>NEUROPSYCHOLOGICAL DISORDERS AND MYASTHENIA GRAVIS: A PILOT STUDY <em>Di Blasi C</em>, Quartuccio ME, Pontecorvo S, Francia A, Prencipe M</td>
</tr>
<tr>
<td>154</td>
<td>ANTI-MUSK PATIENT ANTIBODIES DISRUPT THE MOUSE NEUROMUSCULAR JUNCTION Cole RN, <em>Reddel SW</em>, Gervásio OL, Phillips WD</td>
</tr>
<tr>
<td>156</td>
<td>IMMUNOGLOBULIN G FROM PATIENTS WITH CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP) AFFECTS PRESYNAPTIC TRANSMITTER RELEASE AND CALCIUM INFLUX <em>Bertram S</em>, Zhang W, Toyka KV, Hatt H, Buchwald B</td>
</tr>
</tbody>
</table>
Tuesday, July 7, 2009  
07:30-10:30

“Axonal Protection, Neurobiology”

**Chairs:** Rhona Mirsky and Klaus V. Tokya

<table>
<thead>
<tr>
<th>Time</th>
<th>Title/Author</th>
</tr>
</thead>
</table>
| 07:30-08:30| **SPECIAL SESSION**  
BASIC SCIENCE FOR CLINICIANS  
Steven S. Scherer and Lawrence Wrabetz |
| 09:00-09:30| **PLENARY LECTURE 5**  
NEURON-GLIA SIGNALLING AND THE PROTECTION OF AXON FUNCTION BY SCHWANN CELLS  
Klaus-Armin Nave |
| 09:30-09:45| DLG1 COORDINATES A HOMEOSTATIC CONTROL OF MYELINATION VIA SEC8 AND MTMR2 INTERACTION  
Bolis A, Coviello S, Visigalli I, Taveggia C, Chishti AH, Quattrini A, Previtali SC, Biffi A, **Bolino A** |
| 09:45-10:00| EXPRESSION AND ACTIVITY OF THE SODIUM-DEPENDENT VITAMIN C TRANSPORTER 2 (SVCT2) IS NECESSARY FOR ASCORBIC ACID UPTAKE INTO SCHWANN CELLS  
Gess B, Halfter H, Young P |
| 10:00-10:15| SECRETASES AND NEUREGULIN IN MYELINATION  
La Marca R, Bachi A, Quattrini A, Salzer JL, **Taveggia C** |
| 10:15-10:30| MAGNETIC RESONANCE IMAGING IN FOCAL MOTOR NEUROPATHIES  
**Wessig C**, Bendszus M, Pham M, Reiners K, Toyka K, Stoll G |
### Platform Session 5b

**Tuesday, July 7, 2009**

11:00-12:30

“Hereditary Neuropathies”

**Chairs:** Gian Maria Fabrizi and Pavel Seeman

<table>
<thead>
<tr>
<th>Time</th>
<th>Title/Author</th>
</tr>
</thead>
</table>
| 11:00-11:15| DEVELOPMENT AND CHARACTERIZATION OF A MOUSE MODEL OF CHARCOT-MARIE-TOOTH DISEASE 4C  
| 11:15-11:30| LOSS OF CX32 GAP JUNCTIONS IN SCHWANN CELLS WITH CMT1X MUTATIONS CAUSES PROGRESSIVE DEMYELINATION AND EARLY AXONOPATHY  
Vavlitou N, Sargiannidou I, Hadjisavvas A, Kyriacou K, Scherer SS, **Kleopa KA** |
| 11:30-11:45| TRANSCRIPTOMIC ANALYSIS OF CMT1B MICE REVEALS AN IMPORTANT ROLE FOR TRANSLATIONAL CONTROL IN THE DISEASE PATHOGENESIS  
**D'Antonio M**, Musner N, Tinelli E, Feltri ML, Wrabetz L |
| 11:45-12:00| MCP-1 AND M-CSF ARE PATHOGENETICALLY RELEVANT IN A MOUSE MODEL FOR CMT-1X  
**Groh J**, Fischer S, Martini R |
| 12:00-12:15| DEFINING THE MECHANISM OF AXONAL DEGENERATION FROM MFN2 MUTATIONS IN CMT2A  
**Balah RH**, Misko A |
| 12:15-12:30| BIOCHEMICAL ANALYSIS OF THE H10P MUTATION IN HUMAN MYELIN PROTEIN ZERO  
<table>
<thead>
<tr>
<th>Poster</th>
<th>Title/Author</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>A NOVEL MUTATION IN KIF5A GENE CAUSING HEREDITARY SPASTIC PARAPLEGIA WITH AXONAL NEUROPATHY <strong>Toscano A</strong>, Musumeci O, Mazzeo A, Rossetto MG, Martinuzzi A, Bassi MT</td>
</tr>
<tr>
<td>3</td>
<td>FUNCTIONAL IMPAIRMENT, BUT NOT DEMYELINATION, IS CORRELATED WITH MCP-1 EXPRESSION IN A MOUSE MODEL FOR CMT-1A <strong>Kohl B</strong>, Fischer S, Wessig C, Martini R</td>
</tr>
<tr>
<td>9</td>
<td>SEPT9 ANALYSIS IN A SERIES OF PATIENTS PRESENTING HEREDITARY NEURALGIC AMYOTROPHY (HNA) <strong>Sole G</strong>, Coupry I, Daubos A, Jeandidier E, Verny C, Ferrer X, Goizet C</td>
</tr>
<tr>
<td>13</td>
<td>NERVE CONDUCTION DISTRIBUTION IN CMT1A <strong>Miller LJ</strong>, Laura M, Siskind C, Feely SME, Sottile S, Blake J, Lewis RA, Shy ME, Reilly MM, Marques W Jr</td>
</tr>
<tr>
<td>Poster</td>
<td>Title/Author</td>
</tr>
<tr>
<td>--------</td>
<td>-------------</td>
</tr>
</tbody>
</table>
| 17     | MITOCHONDRIAL DYSFUNCTION IN EXPERIMENTAL CHARCOT-MARIE-TOOTH TYPE 1A (CMT1A) NEUROPATHY  
         **Nobbio L**, Fiorese F, Ravera S, Benvenuto F, Panfoli I, Schenone A |
| 19     | INFLAMMATION DRASTICALLY PROMOTES TRANSTHYRETIN (TTR) DEPOSITION IN THE PERIPHERAL NERVOUS SYSTEM IN AN ANIMAL MODEL OF FAMILIAL AMYLOIDOTIC POLYNEUROPATHY (FAP)  
         **Saraiva MJ**, Gonçalves N |
| 21     | BIOCHEMICAL CHARACTERIZATION OF NERVE AMYLOID IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS PATIENTS WITH AND WITHOUT LIVER TRANSPLANT  
         **Benson MD**, Liepnieks JJ, Zhang Q, Hardwick J |
| 23     | PERIPHERAL NEUROPATHY IN MYOTONIC DYSTROPHY TYPE 1  
         **Hermans MCE**, Faber CG, Vanhoutte EK, Bakkers M, De Baets MH, Merkies ISJ |
| 25     | SPINAL NERVE ROOT THICKENING AND ENHANCEMENT CAUSING PAINFUL AND DISABLING SYMPTOMS IN CMT1A: FAST RECOVERY AFTER HIGH DOSAGE IVIG  
         **Mazzeo A**, Portaro S, Granata F, Vita G, Toscano A |
| 27     | PHENOTYPIC CHARACTERIZATION OF CHARCOT-MARIE-TOOTH DISEASE TYPE 2 ASSOCIATED TO A NOVEL DYNAMIN 2 MUTATION  
         **Berciano J**, Gallardo E, García A, Claeys KG, Nelis E, Canga A, Combarros O, Timmerman V, De Jonghe P |
| 29     | LMNA IS NOT A RELEVANT GENE FOR DIAGNOSTIC TESTING IN AXONAL CHARCOT-MARIE-TOOTH  
| 31     | PATHOPHYSIOLOGICAL MECHANISMS IN LAMIN A/C ASSOCIATED CHARCOT-MARIE-TOOTH DISEASE (CMT2B1)  
<table>
<thead>
<tr>
<th>Poster</th>
<th>Title/Author</th>
</tr>
</thead>
</table>
| 33     | ABNORMAL INTRACELLULAR STORAGE IN LOSS OF FUNCTION OF *Fig4*  
Katona I, Zhang X, Bai Y, Hatfield J, Shy ME, Kupsky WJ, Li J |
| 35     | MUTATIONS IN THE FRABIN GENE CAN CAUSE A VARIABLE PHENOTYPE AND LEAD TO PROTEIN TRUNCATION  
| 37     | PERIPHERAL NEUROPATHY AND VIII CRANIAL NERVE INVOLVEMENT IN FABRY DISEASE  
| 39     | ULTRASTRUCTURAL STUDIES OF PERIPHERAL NERVES IN NDRG1 MUTANT MICE  
King RHM, Nourallah M, Muddle JR, Orrell RW |
| 41     | SEVERE SENSORY NEUROPATHY AS THE PREDOMINANT PRESENTATION OF DNA POLYMERASE GAMMA (POLG) MUTATIONS  
| 43     | FOOT AND ANKLE STRENGTH TRAINING IN PEDIATRIC CMT: A CASE STUDY  
Burns J, Raymond J, Ouvrier RA |
| 45     | DRAMATIC IMPROVEMENT OF PERIPHERAL NERVOUS SYSTEM MANIFESTATIONS OF B-CELL NON-HODGKIN’S LYMPHOMA AFTER RITUXIMAB THERAPY  
| 47     | THE USE OF INTEGRATIVE NEUROLOGY TREATMENTS FOR SYMPTOMATIC RELIEF OF PERIPHERAL NEUROPATHY RESULTING FROM VARIOUS ETIOLOGICAL FACTORS: A BEST CASE SERIES  
Kukurin GW |
<table>
<thead>
<tr>
<th>Poster</th>
<th>Title/Author</th>
</tr>
</thead>
</table>
| 49     | MULTICENTRE, RANDOMISED, OPEN-LABEL TRIAL TO COMPARE EFFICACY AND TOLERANCE OF CORTICOSTEROIDS AND IVIG IN PATIENTS WITH CIDP ON A ONE YEAR FOLLOW UP  
| 51     | COCHRANE REVIEW OF INTERVENTIONS FOR INCREASING ANKLE FLEXIBILITY IN NEUROMUSCULAR DISORDERS  
**Rose KJ**, Burns J, Wheeler D, North KN |
| 53     | PROSPECTIVE STUDY OF EFFICACY OF EXERCISE TRAINING IN SENSORY ATAXIC NEUROPATHIC PATIENTS  
| 55     | PILOT RANDOMISED CONTROLLED TRIAL OF METHOTREXATE FOR CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY (RMC TRIAL): MOTOR NERVE CONDUCTION STUDIES  
**Van den Bergh PYK**, Rutterford CM, Hughes RAC, Mahdi-Rogers M, Piéret F, Guiloff RJ, van Schaik IN; for the RMC Trial Group |
| 57     | INTERLEUKIN 5 (IL-5) PREVENTS AUTOIMMUNE MEDIATED DEMYELINATION BY ACTIVATION OF ANTIGEN SPECIFIC CD4+CD25+ T REGULATORY CELLS  
**Hodgkinson SJ**, Tran GT, Carter N, Verma ND, Plain KM, Robinson CM, Killingsworth M, Boyd R, Hall BM |
| 59     | LRP-1 REGULATES SCHWANN CELL MOTILITY BY ITS EFFECTS ON THE ACTIVITY OF THE GTPASES, RAC AND RHO  
**Mantuano E**, Jo M, Gonias SL, Campana WM |
| 61     | ELECTRICAL STIMULATION COMBINED WITH EXERCISE INCREASE AXONAL REGENERATION AFTER PERIPHERAL NERVE INJURY  
**Udina E**, Asensio-Pinilla E, Jaramillo J, Navarro X |
<table>
<thead>
<tr>
<th>Poster</th>
<th>Title/Author</th>
</tr>
</thead>
</table>
| 63     | BETAII SPECTRIN IS REQUIRED FOR PROPER PERIPHERAL NERVE MYELINATION  
         **Susuki K**, Ogawa Y, Stankewich MC, Rasband MN |
| 65     | PHOSPHORYLATION OF NF-M KSP REPEATS IS NOT REQUIRED FOR RADIAL AXONAL GROWTH  
         **Garcia ML**, Rao MV, Garcia VB, Ellisman M, Calcutt NA, Cleveland DW |
| 67     | BEHAVIOURAL AND ANATOMICAL ANALYSIS OF SELECTIVE TIBIAL NERVE BRANCH NEUROTIZATION TO THE DEEP PERONEAL NERVE IN THE RAT  
         **Kemp SWP**, Alant J, Webb AA, Midha R |
| 69     | THE INVESTIGATION OF REGENERATING NERVE, SCHWANN CELL MIGRATION AND ANGIOGENESIS IN BIODEGRADABLE PERIPHERAL NERVE CONDUIT WITH DDS OF FGF2  
         **Takamatsu K**, Okada M, Sakaguchi K, Yano K, Uemura T, Kazuki K |
| 71     | MEASURING CHANGES IN THE SPATIOTEMPORAL DISTRIBUTION OF TARGET INNERVATION IN THE ADULT MOUSE: NEW METHODS TO STUDY AXONAL DEGENERATION AND REGENERATION  
         **Polley MA**, Hoffman PN, Pan B, Griffin JW |
| 73     | ANALYSIS OF THE STRESS TRANSDUCER, PERK, IN SCIATIC NERVES OF THE CMT 1B NEUROPATHY MOUSE  
         **Musner N**, D’Antonio M, Zambroni D, Feltri ML, Wrabetz L |
| 75     | SKIN-DERIVED PRECURSOR CELLS SECRETE BIOACTIVE FACTORS THAT ENHANCE REGENERATION THROUGH THE CHRONICALLY DENERVATED NERVE  
         **Walsh SK**, Gordon T, Midha R |
| 77     | DIFFUSION TENSOR TRACTOGRAPHY OF PERIPHERAL NERVE AFTER CONTUSIVE INJURY  
         **Takagi T**, Nakamura M, Yamada M, Hikishima K, Momoshima S, Fujiyoshi K, Shibata S, Okano HJ, Toyama Y, Okano H |
<table>
<thead>
<tr>
<th>Poster</th>
<th>Title/Author</th>
</tr>
</thead>
<tbody>
<tr>
<td>79</td>
<td>SIDE-TO-SIDE NERVE GRAFTS “PROTECT” CHRONICALLY DENERVATED NERVE PATHWAYS DURING AXON REGENERATION RESULTING IN IMPROVED FUNCTIONAL REINNERVATION Ladak A, Schembri P, Tyreman N, Udina E, Gordon T</td>
</tr>
<tr>
<td>81</td>
<td>NEURONAL CADHERIN IS REQUIRED FOR OPTIMAL NEURITE OUTGROWTH ON ASTROCYTES Ferguson TA, Scherer SS</td>
</tr>
<tr>
<td>83</td>
<td>TOPIRAMATE MODULATES AXONAL ION CHANNEL FUNCTION IN VIVO Krishnan AV, Park SB, Lin CS-Y, Zagami AS, Kiernan MC</td>
</tr>
<tr>
<td>85</td>
<td>4-HYDROXY-2-NONENAL MODIFIES MITOCHONDRIAL PROTEINS, IMPAIRS MITOCHONDRIAL ACTIVITY AND CAUSES SUBOPTIMAL AXONAL OUTGROWTH IN CULTURED ADULT SENSORY NEURONS Akude E, Zherebitskaya E, Chowdhury SKR, Fernyhough P</td>
</tr>
<tr>
<td>87</td>
<td>NEUROTOXICITY AND NEUROPROTECTION ASSAYS IN AN IN VITRO MODEL OF DIABETIC NEUROPATHY Camozzi F, Taiana M, Melli G, Lauria G</td>
</tr>
<tr>
<td>89</td>
<td>ANTI-GANGLIOSIDE AUTOANTIBODIES IN TYPE 1 DIABETES Lucchetta M, Rudiloso S, Costa S, Albedini A, Briani C</td>
</tr>
<tr>
<td>91</td>
<td>THE NEUROTOXICITY-INDUCED NEUROBLASTOMA APOPTOSIS (NINA) ASSAY PREDICTS A ROLE FOR SERUM LIPOPROTEINS IN THE DEVELOPMENT OF DIABETIC NEUROPATHY Kulbey H, Burcus N, Vinik AI, Pittenger GL</td>
</tr>
<tr>
<td>93</td>
<td>ELEVATED TRIGLYCERIDES CORRELATE WITH PROGRESSION OF DIABETIC NEUROPATHY Wiggin TD, Sullivan KA, Pop-Busui R, Amato A, Sima AAF, Feldman EL</td>
</tr>
<tr>
<td>Poster</td>
<td>Title/Author</td>
</tr>
<tr>
<td>--------</td>
<td>-------------</td>
</tr>
<tr>
<td>95</td>
<td>SIMPLE COUNTERSTAINING WITH HEMATOXYLIN AND EOSIN RESULTS IN HIGHER LEVELS OF INTRAEPIDERMAL NERVE FIBRE COUNTS IN SKIN BIOPSIES <strong>Mellgren SI</strong>, Olsen E, Løseth S, Lindal S, Nebuchennykh M</td>
</tr>
<tr>
<td>97</td>
<td>EXTENSOR DIGITORUM BREVIS MUSCLE IN DIABETIC PATIENTS <strong>Baba M</strong>, Suzuki C, Arai A, Miki Y, Nunomura J, Kimura T, Tomiyama M</td>
</tr>
<tr>
<td>99</td>
<td>SENSORY NEUROPATHY ASSOCIATED TO GLUCOSE INTOLERANCE: A 35 PATIENT STUDY <strong>Quintanilha G</strong>, Nascimento OJM</td>
</tr>
<tr>
<td>101</td>
<td>PAINFUL SENSORY NEUROPATHY IN ELDERLY PATIENTS <strong>Bursova S</strong>, Vickova-Moravcova E, Bednarik J</td>
</tr>
<tr>
<td>103</td>
<td>DULOXETINE AND PREGABALIN IN DIABETIC NEUROPATHIC PAIN <strong>Conti G</strong>, Bresolin N</td>
</tr>
<tr>
<td>105</td>
<td>NEUREGULIN-ERBB SIGNALLING CONTRIBUTES TO MICROGLIOSIS AND PAIN FOLLOWING PERIPHERAL NERVE INJURY <strong>Calvo M</strong>, Zhu N, Grist J, Bennett DLH</td>
</tr>
<tr>
<td>107</td>
<td>ELEVATED PRO-INFLAMMATORY CYTOKINE GENE EXPRESSION IN AFFECTED SKIN OF PATIENTS WITH SMALL FIBER NEUROPATHY <strong>Üçeyler N</strong>, Kafke W, Riediger N, He L, Toyka KV, Sommer C</td>
</tr>
<tr>
<td>109</td>
<td>FOLLOW-UP STUDY AND RESPONSE TO TREATMENT IN 18 PATIENTS WITH LEWIS-SUMNER SYNDROME <strong>Attarian S</strong>, Verschueren A, Salort-Campana E, Franques J, Azulay JP, Pouget J</td>
</tr>
<tr>
<td>Poster</td>
<td>Title/Author</td>
</tr>
<tr>
<td>--------</td>
<td>-------------</td>
</tr>
</tbody>
</table>
| 111    | DEMYELINATING NEUROPATHY DEVELOPED DURING INTERFERON-BETA THERAPY IN A PATIENT WITH MULTIPLE SCLEROSIS  
**Suzuki C**, Baba M, Arai A, Miki Y, Nunomura J, Kimura T, Tomiyama M |
| 113    | COMBINING SENSORY MODALITIES WITHIN A SENSORY SUM SCORE: ARE WE PICKING UP GOOD VIBRATIONS?  
**Pace AA**, Hughes RAC, van Schaik IN, Hobart JC; for the RMC Trial Group |
| 115    | MULTIPLE EXCITABILITY PROPERTIES IN CLINICALLY IDENTIFIED PERIPHERAL NEUROPATHIES  
| 117    | SURAL NERVE BIOPSY FINDINGS IN CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY WITH DIABETES MELLITUS, COLLAGEN DISEASES AND HEPATITIS  
El-Etribi MA, Mohamed SA, El-Hefnawy NG, El-Wahab Reda RA, El-Maguid Shaheen HA, **El-Mously SM** |
| 119    | IMPROVING FATIGUE ASSESSMENT IN IMMUNE-MEDIATED NEUROPATHIES: THE MODIFIED RASCH-BUILT FATIGUE SEVERITY SCALE  
**van Nes SI**, Vanhoutte E, Faber C, Garssen M, van Doorn PA, Merkies ISJ; on behalf of the PeriNomS study group |
| 121    | INVOLVEMENT OF TYPE 1 AND TYPE 17 IMMUNITY IN CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY  
| 123    | CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY DISEASE ACTIVITY STATUS (CDAS): RECOMMENDATIONS FOR CLINICAL RESEARCH STANDARDS  
<table>
<thead>
<tr>
<th>Poster</th>
<th>Title/Author</th>
</tr>
</thead>
</table>
| 125    | A RANDOMIZED CONTROLLED TRIAL OF RITUXIMAB IN DEMYELINATING NEUROPATHY ASSOCIATED WITH ANTI-MAG IGM GAMMOPATHY (RIMAG STUDY): STUDY DESIGN AND PROGRESS REPORT  
**Bombelli F**, Bessirard V, Viala K, Léger J-M; for the RIMAG Trial Group (France and Switzerland) |
| 127    | ANTI-GANGLIOSIDE ANTIBODIES IN MULTIFOCAL MOTOR NEUROPATHY: FREQUENCY, SPECIFICITY AND ASSOCIATION WITH WEAKNESS AND DISABILITY  
**Cats EA**, Jacobs BC, van den Berg LH, Yuki N, Tio-Gillen AP, van der Pol W-L |
| 129    | NEUROPATHY IN A POPULATION WITH INFLAMMATORY BOWEL DISEASE IN OLMSTEAD COUNTY, MINNESOTA  
**Figueroa JJ**, Dyck PJB, Loftus EV, Klein CJ |
| 131    | WARTENBERG’S MIGRANT SENSORY NEURITIS: A PROSPECTIVE FOLLOW-UP STUDY  
**Stork ACJ**, van der Meulen MM, van der Pol W-L, Vranken AFJE, Franssen H, Notermans NC |
| 133    | CHARACTERIZATION OF NEUROPATHOPHYSIOLOGICAL EFFECTS OF ANTI-GANGLIOSIDE COMPLEX SERA AT THE MOUSE NEUROMUSCULAR JUNCTION  
Zitman FM, Greenshields KN, Kuijf ML, Kaida K, Jacobs BC, Kusunoki S, Willison HJ, **Plomp JJ** |
| 135    | ELECTROPHYSIOLOGICAL CHARACTERISTICS AND THEIR RELATION TO TREATMENT RESPONSE IN IGM MGUS POLYNEUROPATHY  
**Niermeijer JMF**, Notermans NC, Teunissen L, Wokke JHJ, Franssen H |
| 137    | APPEARANCE OF CONDUCTION BLOCKS IN MULTIFOCAL MOTOR NEUROPATHY AFTER IVIG TREATMENT  
**Ajroud-Driss S**, Sufit R |
<table>
<thead>
<tr>
<th>Poster</th>
<th>Title/Author</th>
</tr>
</thead>
</table>
| 139    | FACIAL DIPLEGIA AS A SOLE MANIFESTATION OF GUILLAIN-BARRÉ SYNDROME  
Kim JK, Bae JS, Oh SY, Sohn EH, Hong YH |
| 141    | ANTIBODY TITERS PREDICT CLINICAL FEATURES IN AUTOIMMUNE AUTONOMIC GANGLIONOPATHY  
Gibbons CH, Freeman R |
| 143    | A COMPLEX CONSISTING OF GM1 AND GalNAc-GD1a: A TARGET FOR PURE MOTOR GUILLAIN-BARRÉ SYNDROME  
Kaida K, Ogawa G, Kamakura K, Motoyoshi K, Ueda-Sada M, Kusunoki S, Sonoo M, Arita M |
| 145    | PAIN AND AUTONOMIC DYSFUNCTION IN PATIENTS WITH SARCOIDOSIS AND SMALL FIBER NEUROPATHY  
Bakkers M, Faber CG, Lauria G, Hermans MCE, van Nes SI, Drent M, de Baets M, Merkies ISJ |
| 147    | PROMINENT DEMYELINATION IN VASCULITIC NEUROPATHY  
Wang M, Pollard JD, Nguyen T, Spies J |
| 149    | MULTIFOCAL NEUROPATHIES AND AN ALS CLINICAL PRESENTATION  
Fisher MA, Venizelos AP |
| 151    | THYMOMA-ASSOCIATED MYASTHENIA GRAVIS AND INCLUDED BODY MYOSITIS: AN UNUSUAL COMBINATION OF DISEASES  
Pontecorvo S, Di Blasi C, Morreale M, Francia A, Prencipe M |
| 153    | RECURRENT SPONTANEOUSLY IMPROVING MMN-LIKE NEUROPATHY WITH INFlixIMAB  
Umapathi T, Kosa S, Klein CJ |
| 155    | BULBAR VARIANT OF GUILLAIN-BARRÉ SYNDROME: ANALYSIS OF 34 CASES  
Nagashima T, Odaka M, Hirata K, Yuki N |
Tuesday, July 7, 2009  
14:00-15:30

“Hereditary Neuropathies”

**Chairs:** Maria J. Saraiva and Vincent Timmerman

<table>
<thead>
<tr>
<th>Time</th>
<th>Title/Author</th>
</tr>
</thead>
</table>
| 14:00-14:30  | **PLENARY LECTURE 6**  
GENETIC NEUROPATHIES  
Mary M. Reilly |
| 14:30-14:45  | MUTATION ANALYSIS OF GENES FOR HEREDITARY SENSORY AND AUTONOMIC NEUROPATHIES: IDENTIFICATION OF NEW MUTATIONS AND A GENOTYPE-PHENOTYPE CORRELATION STUDY  
| 14:45-15:00  | HIGH-THROUGHPUT MUTATION ANALYSIS OF THE HUMAN AMINOACYL-tRNA SYNTHETASE GENES: IN SEARCH OF ADDITIONAL LOCI RESPONSIBLE FOR INHERITED PERIPHERAL NEUROPATHIES  
| 15:00-15:15  | GENOTYPE PHENOTYPE STUDIES FROM MFN2 MUTATIONS FROM TWO LARGE CMT CLINICS  
Feely SME, Laura M, Siskind CE, Davis M, Gibbons VS, Reilly MM, Shy ME |
| 15:15-15:30  | SHORTENED INTERNODAL LENGTH IN DERMAL MYELINATED NERVE FIBERS OF CMT1A PATIENTS  
Saporta MAC, Katona IK, Shy ME, Li J |
“Hereditary Neuropathies”

**Chairs:** Zarife Sahenk and Ueli Suter

<table>
<thead>
<tr>
<th>Time</th>
<th>Title/Author</th>
</tr>
</thead>
</table>
| 16:00-16:15| **AN IN VITRO MODEL OF MYELIN PROTEIN ZERO MUTATIONS IN SCHWANN CELLS**  
Grandidis M, Scazzola S, Passalacqua M, Luzi P, Bellone E, Mandich P, Shy ME, Schenone A                                                                 |
| 16:15-16:30| **NOVEL MASS SPECTROPHOTOMETRY APPROACH DISTINGUISHES VARIED AMYLOID TYPES IN PERIPHERAL NERVE TISSUE**  
Klein CJ, Dyck PJ, Vrana JA, Mauermann ML, Witt LV, Staff NP, Zeldenrust SR, Bergen RB III, Dogan A                                                                 |
| 16:30-16:45| **A MUTATION OF THE CYTOPLASMIC DYNEIN HEAVY CHAIN GENE Dync1h1 CAUSES A SEVERE SENSORY NEUROPATHY**  
AlQatari M, Vastani N, Bros-Facer V, Groves M, Greensmith L, Fisher EM, Koltzenburg M                                                                 |
| 16:45-17:00| **CONDUCTION BLOCK IN PMP22 DEFICIENCY**  
Bai Y, Zhang X, Katona I, Saporta MA, Shy ME, O’Malley HA, Isom LL, Suter U, Li J                                                                 |
| 17:00-17:45| **PLENARY LECTURE 7**  
*Richard P. Bunge Memorial Lecture*  
AXON-SCHWANN CELL INTERACTIONS THAT PROMOTE MYELINATION  
*James. L. Salzer*  
Introduction by Mary B. Bunge |
**Plenary Lecture 8 and Platform Session 7a**

Wednesday, July 8, 2009  
09:00-10:30

“Therapy”

**Chairs:** Masayuki Baba and Chiara Briani

<table>
<thead>
<tr>
<th>Time</th>
<th>Title/Author</th>
</tr>
</thead>
</table>
| 09:00-09:30  | **PLENARY LECTURE 8**  
CRITICAL ROLE OF THE SirT2 DEACETYLASE IN PERIPHERAL NERVE MYELINATION  
**Jeffrey D. Milbrandt**                                                                 |
| 09:30-09:45  | PULSED HIGH DOSE DEXAMETHASONE TREATMENT VERSUS STANDARD PREDNISOLONE TREATMENT IN CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY (CIDP): A DOUBLE-BLIND, RANDOMISED CONTROLLED CLINICAL TRIAL (PREDICT STUDY)  
**van Schaik IN**, Eftimov F, van Doorn PA, de Haan RJ, Vermeulen M; on behalf of the PREDICT study Group |
| 09:45-10:00  | GENE THERAPY FOR DIABETIC NEUROPATHY USING VIRAL VECTORS CODING FOR NRG1typeIII  
**Ariza L**, Homs J, Noguera E, Pagès G, Chillón M, Navarro X, Corfas G, Bosch A |
| 10:00-10:15  | RANDOMIZED TRIAL OF ASCORBIC ACID FOR CMT1A IN CHILDREN  
| 10:15-10:30  | BIOMATERIAL TO PROMOTE NERVE REGENERATION: TOWARDS CLINICAL TRIALS  
**Cerri F**, Lopez ID, Triolo D, Salvatore L, Del Carro U, Mortini P, Comi G, Sannino A, Quattrini A |
<table>
<thead>
<tr>
<th>Time</th>
<th>Title/Author</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00-11:15</td>
<td>SUPERVISED EXERCISE IMPROVES SMALL FIBER FUNCTION IN DIABETIC SUBJECTS WITHOUT NEUROPATHY</td>
</tr>
<tr>
<td></td>
<td>Singleton JR, Marcus RL, Smith SB, Arsenault C, Burch A, Smith AG</td>
</tr>
<tr>
<td>11:15-11:30</td>
<td>DYSLIPIDEMIA AND PERIPHERAL NEUROPATHY</td>
</tr>
<tr>
<td></td>
<td>Vincent AM, Hayes JM, McLean LL, Vivekanandan-Giri A, Pennathur S, Feldman EL</td>
</tr>
<tr>
<td>11:30-11:45</td>
<td>AXONAL TRANSPORT OF VASCULAR ENDOTHELIAL GROWTH FACTOR TO THE DORSAL ROOT GANGLIA IN EXPERIMENTAL DIABETIC NEUROPATHY</td>
</tr>
<tr>
<td></td>
<td>Pawson EJ, Duran-Jimenez B, Tomlinson DR, Gardiner NJ</td>
</tr>
<tr>
<td>11:45-12:00</td>
<td>EARLY PROTECTION FROM SENSORY ABNORMALITIES IN DIABETIC MICE WITH OVEREXPRESSION OF HUMAN HEAT SHOCK PROTEIN 27</td>
</tr>
<tr>
<td></td>
<td>Korngut L, Ma CHE, Martinez JA, Toth CC, Woolf CJ, Zochodne DW</td>
</tr>
<tr>
<td>12:00-12:15</td>
<td>EFFECTS OF PRIOR INTENSIVE INSULIN THERAPY ON CARDIAC AUTONOMIC NERVOUS SYSTEM FUNCTION IN TYPE 1 DIABETES: THE DIABETES CONTROL AND COMPLICATIONS TRIAL/EPIDEMIOLOGY OF DIABETES INTERVENTIONS AND COMPLICATIONS STUDY (DCCT/EDIC)</td>
</tr>
<tr>
<td></td>
<td>Pop-Busui R, Low PA, Waberski BH, Martin CL, Albers JW, Feldman EL, Sommer C, Cleary P, Lachin JM, Herman WH; and the DCCT/EDIC Research Group</td>
</tr>
<tr>
<td>12:15-12:30</td>
<td>INCREASED NERVE FIBER REGENERATION AND NEUROTROPHIC SUPPORT IN LONG-TERM DIABETIC STZ-RATS TRANSPLANTED WITH ADIPOSE-TISSUE-DERIVED MESENCHYMAL STEM CELLS</td>
</tr>
<tr>
<td></td>
<td>Yagihashi S, Mizukami H, Yamagishi S, Ogasawara S, Sugimoto K, Baba M</td>
</tr>
<tr>
<td>12:30-12:40</td>
<td>FAREWELL ADDRESS</td>
</tr>
<tr>
<td></td>
<td>Title/Author</td>
</tr>
<tr>
<td>---</td>
<td>-------------</td>
</tr>
</tbody>
</table>
| 2 | THE PHENOTYPE OF THE GLY94FSX222 PMP22 INSERTION  
de Vries S, **van der Kooi AJ**, Verhamme C, van Ruissen F,  
Arts WF, Mauser H, Kerkhoff H, van Engelen B, de Visser M,  
Baas F |
| 4 | RECESSIVE SPASTIC ATAXIA OF CHARLEVOIX-SAGUENAY:  
PERIPHERAL NERVE INVOLVEMENT WITH INTERMEDIATE-  
RANGE OF MOTOR NERVE CONDUCTION VELOCITY  
**García A**, Berciano J, Criscuolo C, de Michele G |
| 6 | LATE ONSET HEREDITARY SENSORY NEUROPATHY TYPE 1  
(HSN1) CAUSED BY A NOVEL P.C133R MISSENSE MUTATION  
in SPTLC1  
**Rautenstrauss B**, Neitzel B, Muench C, Haas J, Holinski-Feder  
E, Abicht A |
| 8 | STUDY OF FEMALES WITH CHARCOT-MARIE-TOOTH DISEASE  
TYPE 1X  
Hyman E, Sottile S, Ramchandren S, Shy ME, **Siskind CE** |
| 10 | COEXISTENCE OF ADULT POLYGLUCOSAN BODY DISEASE AND  
FABRY DISEASE  
**Marchesi C**, Pagliarani S, Savoiardo M, Morandi L, Lucchiari S,  
Salsano E, Comi GP, Pareyson D |
| 12 | CSN5/JAB1 REGULATES SCHWANN CELL-AXON INTERACTION  
AND PLAYS A ROLE IN PERIPHERAL NERVE DEVELOPMENT AND  
FUNCTION  
**Porrello E**, Cerri F, Dina G, Triolo D, Lopez ID, Panattoni M,  
Del Carro U, Morana P, Comi G, Wrabetz L, Feltri ML, Pardi R,  
Quattrini A, Previtali SC |
| 14 | DIAGNOSTIC PITFALLS IN TRANSTHYRETIN-RELATED  
FAMILIAL AMYLOID POLYNEUROPATHIES (TTR-FAPS)  
Cappellari M, Ferrarini M, Taioli F, Cavallaro T, Ferrari S,  
Rizzuto N, **Fabrizi GM** |
<table>
<thead>
<tr>
<th>Poster</th>
<th>Title/Author</th>
</tr>
</thead>
</table>
| 16     | FOUR NOVEL MUTATIONS OF MYELIN PROTEIN ZERO GENE ASSOCIATED WITH A VERY MILD AND LATE ONSET POLYNEUROPATHY<br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br>
<table>
<thead>
<tr>
<th>Poster</th>
<th>Title/Author</th>
</tr>
</thead>
<tbody>
<tr>
<td>32</td>
<td>ABNORMAL PERIPHERAL NERVE EXCITABILITY IN MICE DEFICIENT OF THE MYELIN PROTEIN P0&lt;br&gt;Moldovan M, Alvarez S, Pinchenko V, Nielsen FC, Martini R, Krarup C</td>
</tr>
<tr>
<td>34</td>
<td>MULTIPLE ANALYSIS OF HEREDITARY SPASTIC PARAPLEGIA&lt;br&gt;Akcakaya NH, Atay C, Isik N, Uludağ FI, Deymeer F, Serdaroglu P, Battaloglu E, Parman Y</td>
</tr>
<tr>
<td>36</td>
<td>AUTONOMIC DYSFUNCTION IN HEREDITARY NEUROPATHY CMT&lt;br&gt;Mazanec R, Vyhnálek M, Marčišová H, Seeman P, Bojar M, Nedělka T</td>
</tr>
<tr>
<td>38</td>
<td>EXPLORING PARALLELS BETWEEN MOLECULAR CHANGES INDUCED IN PNS BY AGING AND DEMYELINATING NEUROPATHIES&lt;br&gt;Verdier V, De Preux Charles A-S, Verheijen MHG, Chrast R</td>
</tr>
<tr>
<td>40</td>
<td>CORTICOBULBAR AND CORTICOSPINAL TRACT INVOLVEMENT IN KENNEDY’S DISEASE&lt;br&gt;Versace V, Rocchi C, Pachatz C, Rainone M, Terracciano C, Massa R, Marfia GA</td>
</tr>
<tr>
<td>42</td>
<td>DETERIORATION OF NEUROMUSCULAR FUNCTION IN ADULT CMT1A PATIENTS IS IN THE RANGE OF NORMAL AGING: A 5-YEAR NATURAL HISTORY STUDY&lt;br&gt;Verhamme C, van Schaik IN, Koelman JHTM, de Haan RJ, de Visser M</td>
</tr>
<tr>
<td>44</td>
<td>RELAPSING AIDP RESPONSIVE TO INTRAVENOUS IMMUNOGLOBULIN IN POEMS SYNDROME&lt;br&gt;Terracciano C, Fiore S, Marfia GA, Versace V, Doldo E, Albonici L, Massa R</td>
</tr>
<tr>
<td>46</td>
<td>ITALIAN REGISTER OF THERAPY RESPONSE IN PATIENTS WITH CHRONIC DEMYELINATING INFLAMMATORY POLYNEUROPATHY&lt;br&gt;Cocito D, Paolasso I, Antonini G, Benedetti L, Briani C, Comi C, Fazio R, Jann S, Matà S, Mazzeo A, Sabatelli M, Nobile-Orazio E; and The Italian Network for CIDP Register</td>
</tr>
<tr>
<td>Poster</td>
<td>Title/Author</td>
</tr>
<tr>
<td>--------</td>
<td>--------------</td>
</tr>
</tbody>
</table>
| 48     | USE OF DULOXETINE IN PERIPHERAL NEUROPATHIC PAIN: EXPERIENCE OF A NEUROIMMUNOLOGIC CENTRE  
**Di Blasi C**, Pontecorvo S, Morreale M, Quartuccio ME, Prencipe M, Francia A |
| 50     | GENE THERAPY FOR DIABETIC NEUROPATHY BY INTRATHECAL ADMINISTRATION OF ADENO-ASSOCIATED VECTORS CODING FOR IGF-1  
**Homs J**, Ariza L, Udina E, Chillón M, Navarro X, Bosch A |
| 52     | RITUXIMAB-TREATED CIDP: A RETROSPECTIVE STUDY  
| 54     | LACK OF THERAPEUTIC EFFECT OF BONE MARROW-DERIVED MESENCHYMAL STEM CELLS IN A MODEL OF GUILLAIN-BARRÉ SYNDROME  
**Sajic M**, Hunt D, Gregson NA, Chandran S, Smith KJ |
| 56     | APPROPRIATENESS OF PRE-SURGICAL INSTRUMENTAL DIAGNOSTIC TECHNIQUES FOR TRAUMATIC BRACHIAL PLEXUS INJURIES  
| 58     | MULTICENTER, RANDOMIZED, CONTROLLED TRIAL ON THE EFFICACY AND TOLERABILITY OF HIGH DOSE INTRAVENOUS IMMUNOGLOBULIN IN TREATMENT RESISTANT NEUROPATHIC PAIN  
**Jann S**, Francia A, Fruguglietti ME, Sterzi R |
| 60     | THE CYCLIN-DEPENDENT KINASE INHIBITOR p57kip2 IS A NEGATIVE REGULATOR OF SCHWANN CELL DIFFERENTIATION AND IN VITRO MYELINATION  
<table>
<thead>
<tr>
<th>Poster</th>
<th>Title/Author</th>
</tr>
</thead>
<tbody>
<tr>
<td>62</td>
<td>INTERNALIZATION OF TRANSTHYRETIN BY DRG NEURONS IS MEGALIN-CLATHRIN MEDIATED AND NEEDED FOR ITS ABILITY TO INCREASE NEURITE OUTGROWTH <strong>Mar FM</strong>, Fleming CE, Franquinho F, Saraiva MJ, Sousa MM</td>
</tr>
<tr>
<td>64</td>
<td>PERIPHERAL NEUROPATHY IN EBF2 NULL MICE <strong>Giacomini C</strong>, La Padula V, Leandri M, Goutebroze L, Consalez GG, Benfenati F, Schenone A, Corradi A</td>
</tr>
<tr>
<td>68</td>
<td>TRUE RESIDENT ENDONEURIAL MACROPHAGES IN THE PNS OR NOT: A STUDY OF PHYSIOLOGICAL MACROPHAGE TURNOVER IN BONE MARROW CHIMERIC MICE <strong>Müller M</strong>, Leonhard C, Wacker K, Kiefer R</td>
</tr>
<tr>
<td>70</td>
<td>SENSORY AXON-DERIVED NEUREGULIN-1 IS REQUIRED FOR AXOGIAL SIGNALLING AND NORMAL SENSORY FUNCTION BUT NOT FOR LONG TERM AXON MAINTENANCE <strong>Fricker FR</strong>, Zhu N, Abrahamsen B, Nassar MA, Thakur M, Garratt AN, Birchmeier C, McMahon SB, Wood JN, Bennett DLH</td>
</tr>
<tr>
<td>72</td>
<td>ACCELERATED AXONAL REGENERATION IN THE INJURED PERIPHERAL NERVE OF BACE1 KNOCKOUT MICE <strong>Farah MH</strong>, Polley MA, Hoffman PN, Taube R, Wong PC, Griffin JW</td>
</tr>
<tr>
<td>74</td>
<td>REGENERATION SUPER SENSITIVITY AFTER INJECTION OF BOTULINUM TOXIN <strong>Schlereth T</strong>, Geber C, Hannemann S, Birklein F</td>
</tr>
<tr>
<td>76</td>
<td>ALTERATIONS IN GLUTAMATE UPTAKE IN AN IN VITRO MODEL OF CISPLATIN-NEUROTOXICITY <strong>Carozzi VA</strong>, Zoia C, Ceresa C, Ferrarese C, Cavaletti G</td>
</tr>
<tr>
<td>Poster</td>
<td>Title/Author</td>
</tr>
<tr>
<td>--------</td>
<td>-------------</td>
</tr>
</tbody>
</table>
| 78     | MORPHOLOGICAL DIFFERENCES IN AORTIC DEPRESSOR NERVES OF RATS AND MICE: IMPLICATIONS FOR UNDERSTANDING THE MOLECULAR/STRUCTURAL BASIS OF BARORECEPTOR FUNCTION  
**Fazan VPS, de Santana Filho VJ, Fazan R Jr, Salgado HC, Moore KC, Chapleau MW** |
| 80     | SYNTHESIS OF GABA IN SCHWANN CELLS IS INDUCED BY THE NEUROACTIVE STEROID ALLOPREGNANOLONE  
**Magnaghi V, Bonanno G, Faroni A, Parducz A, Fumagalli F** |
| 84     | CIRCULATING INFLAMMATORY MARKERS ASSOCIATED WITH DIABETIC NEUROPATHY  
**Gibbons CH, Freeman R, Veves A** |
| 86     | SUDOMOTOR FUNCTION IN DIABETIC SUBJECTS: EVALUATION BY DYNAMIC SWEAT TEST (DST)  
**Provitera V, Nolano M, Caporaso G, Stancanelli A, Santoro L** |
| 88     | NEUROPHYSIOLOGICAL AND HISTOLOGICAL CHARACTERIZATION OF BORTEZOMIB-INDUCED NEUROPATHY IN MICE  
| 90     | SINGLE FIBER CONDUCTION VELOCITY IMPROVES NEUROPHYSIOLOGICAL SENSITIVITY FOR DIAGNOSIS OF NEUROPATHY IN DIABETIC PATIENTS  
**Padua L, Caliandro P, Pazzaglia C, Granata G, Tonali P** |
| 92     | CHARACTERIZATION OF GLYOXALASE I IN STREPTOZOCIN-INDUCED DIABETES MOUSE MODELS OF PAINFUL AND INSENSATE NEUROPATHY  
**Dunn MM, Ryals JM, Wright DE** |
| 96     | LARGE AND SMALL NERVE FIBER INVOLVEMENT IN PATIENTS WITH HYPOTHYROIDISM  
Nebuchennykh M, Løseth S, **Mellgren SI** |
<table>
<thead>
<tr>
<th>Poster</th>
<th>Title/Author</th>
</tr>
</thead>
</table>
| 98     | A CONVENIENT AND APPROPRIATE CLINICAL EVALUATION OF DIABETIC NEUROPATHY  
**Hasegawa O**, Kawasaki A, Ohta M, Kawasaki A, Saito M |
| 100    | FUNCTIONAL RECOVERY WITH SYNGENEICALLY TRANSPLANTED MICROCAPSULATED PANCREATIC ISLETS IN STREPTOZOTOCIN-INDUCED DIABETIC RATS  
| 102    | OCCURRENCE AND CHARACTERISATION OF PAIN IN DYSIMMUNE NEUROPATHIES  
**Caliandro P**, Granata G, Pazzaglia C, Briani C, Padua L |
| 104    | AMITRIPTYLINE BLOCKS THE DEPOLARISING EFFECT OF NICOTINE IN UNMYELINATED PERIPHERAL HUMAN AXONS  
Freysoldt A, Fleckenstein J, Lang PM, Irnich D, Carr RW, **Grafe P** |
| 106    | TRIGEMINAL CUTANEOUS INNERVATION IN NORMAL SUBJECTS  
**Nolano M**, Truini A, Provitera V, Stancanelli A, Cruccu G, Santoro L |
| 108    | GENE EXPRESSION OF CYTOKINES AND NEUROTROPHIC FACTORS IN SURAL NERVE BIOPSY SPECIMENS OF PATIENTS WITH PAINFUL AND PAINLESS POLYNEUROPATHY  
**Üçeyler N**, Riediger N, Kafke W, Lan H, Toyka KV, Sommer C |
| 110    | DETECTION OF ANTI-MAG ANTIBODIES IN POLYNEUROPATHY ASSOCIATED WITH IGM MONOCLONAL GAMMOPATHY  
Kuijf ML, Eurelings M, Tio-Gillen AP, van Doorn PA, van den Berg LH, Stor J, Notermans NC, **Jacobs BC** |
| 112    | PREDICTION OF MECHANICAL VENTILATION IN GUILLAIN-BARRÉ SYNDROME  
**Walgaard C**, Lingsma HF, Drenthen J, Steyerberg EW, van Doorn PA, Jacobs BC |
<table>
<thead>
<tr>
<th>Poster</th>
<th>Title/Author</th>
</tr>
</thead>
<tbody>
<tr>
<td>114</td>
<td>RANDOMISED TRIAL OF METHOTREXATE IN CIDP (RMC) STUDY: DID THE MEASUREMENT OF STRENGTH PROVE TO BE A WEAKNESS? <strong>Pace AA</strong>, Hughes RAC, van Schaik IN, Hobart JC; for the RMC Trial Group</td>
</tr>
<tr>
<td>116</td>
<td>ANTI-GANGLIOSIDE COMPLEX IgM ANTIBODIES IN MULTIFOCAL MOTOR NEUROPATHY Terenghi F, Giannotta C, Sonnino S, <strong>Nobile-Orazio E</strong></td>
</tr>
<tr>
<td>118</td>
<td>NERVE FIBER ATROPHY PATTERN IN VASCULITIC NEUROPATHY AND CHRONIC DEMYELINATING NEUROPATHY <strong>Kizilay F</strong>, Oh SJ</td>
</tr>
<tr>
<td>120</td>
<td>ACTIVITY INDUCED WEAKNESS IN IMMUNE MEDIATED POLYNEUROPATHIES <strong>Straver DCG</strong>, van den Berg LH, van den Berg-Vos RM, Franssen H</td>
</tr>
<tr>
<td>126</td>
<td>SEVERE GUILLAIN-BARRÉ SYNDROME: SORTING OUT THE PATHOLOGICAL HALLMARK IN AN ELECTROPHYSIOLOGIC AXONAL CASE <strong>Berciano J</strong>, García A, Villagrá NT, González F, Ramón C, Illa I, Berciano MT, Lafarga M</td>
</tr>
<tr>
<td>Poster</td>
<td>Title/Author</td>
</tr>
<tr>
<td>--------</td>
<td>-------------</td>
</tr>
</tbody>
</table>
| 128    | AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN POEMS SYNDROME  
| 130    | SUBCUTANEOUS IMMUNOGLOBULIN AS MAINTENANCE THERAPY IN INTRAVENOUS IMMUNOGLOBULIN-RESPONSIVE CIDP PATIENTS. LONG-TERM RESPONSE IN 16 PATIENTS  
   **Magy L**, Ghorab K, Calvo J, Vallat J-M |
| 132    | WALDENSTRÖM-ASSOCIATED NEUROPATHY: DIFFERENT PATHOGENIC MECHANISMS CONTRIBUTE TO NERVE DAMAGE  
| 134    | DIFFERENT FUNCTIONAL ROLES OF CCR2 IN MYELIN PROTEIN ZERO (P0) DEFICIENT MICE  
   **Oberländer M**, Fischer S, Müller M, Berghoff M |
| 136    | IMPACT OF SELECTIVE DECONTAMINATION OF THE DIGESTIVE TRACT (SDD) ON DURATION OF MECHANICAL VENTILATION AND NEUROLOGICAL RECOVERY IN PATIENTS WITH GUILLAIN-BARRÉ SYNDROME  
| 138    | ACUTE IDIOPATHIC POLYNEUROPATHY AFTER SUBCUTANEOUS ALENTEZUMAB (AL) THERAPY IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS  
   **Reda G**, Castelli R, Aprile von Hohenstaufen K, Orofino N, Conti G, Cortelezzi A, Bresolin N |
| 140    | T CELL RESPONSE IN ACUTE MOTOR AXONAL NEUROPATHY  
   **Notturno F**, Cencioni MT, Caporale CM, Creati B, Prencipe V, Battistini L, Uncini A |
| 142    | INITIAL SYMPTOMS, INTERCURRENT EVENTS AND LONG-TERM DISABILITY IN GBS AND CIDP  
   **Kuitwaard K**, Bos-Eyssen ME, Blomkwist-Markens PH, van Doorn PA |
<table>
<thead>
<tr>
<th>Poster</th>
<th>Title/Author</th>
</tr>
</thead>
<tbody>
<tr>
<td>144</td>
<td>A COMPARATIVE CLINICAL AND IMMUNOLOGICAL STUDY OF DYSIMMUNE AND IDIOPATHIC SENSORY NEURONOPATHY Antoine J-C, Lassablière F, Jousserand G, <strong>Camdessanché J-P</strong></td>
</tr>
<tr>
<td>146</td>
<td>KINETIC STUDIES OF GENE REGULATION BY SCHWANN CELLS INDUCED BY CYCLIC ADENOSINE MONOPHOSPHATE IN VITRO <strong>Lisak RP</strong>, Bealmear BM, Benjamins JA, Xu W, Yao B, Land S</td>
</tr>
<tr>
<td>150</td>
<td>HIV ASSOCIATED SENSORY NEUROPATHY: LENGTH DEPENDENT ACCUMULATION OF MITOCHONDRIAL DNA DELETIONS IN HUMANS REFLECTS SPATIAL DIFFERENCES OF MITOCHONDRIAL FUNCTION IN THE SIMIAN IMMUNODEFICIENCY VIRUS (SIV) MACAQUE MODEL <strong>Lehmann HC</strong>, Mankowski JL, Borzan J, Höke A</td>
</tr>
<tr>
<td>152</td>
<td>PARANEOPLASTIC GANGLIONITIS ASSOCIATED WITH LARGE CELL LUNG CARCINOMA: A PATHOLOGIC STUDY <strong>Krishna V</strong>, Coons S, Sivakumar K, Ladha S</td>
</tr>
</tbody>
</table>